Die Hammeraktie!!!!!Combimatrix!Check out the NEWS!!Nano Pur!!Das ist mein Geheimtip! - 500 Beiträge pro Seite

[Gluewuermchen]

Die wird alle outperformen!


Press Release Source: Acacia Research Corporation

CombiMatrix and Washington University in St. Louis Collaborate on Nanoscale Synthesis of Chemical Libraries
Tuesday January 20, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 20, 2004--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix Group and Washington University in St. Louis are collaborating to develop a system for the synthesis of libraries of diverse, non-nucleic acid molecules. These libraries will be synthesized using CombiMatrix`s semiconductor based microarrays and electrochemical synthetic methods. CombiMatrix NanoArrays(TM) will be used for the diverse chemical synthesis.

The research at Washington University in St. Louis is being funded by a grant from the National Science Foundation. Professor Kevin D. Moeller, Principle Scientist on the NSF grant, is exploring the capabilities of the CombiMatrix technology platform for building spatially addressed diverse molecular libraries on a chip.

CombiMatrix`s NanoArrays(TM) incorporate thousands of independently addressable micro-electrodes on a semiconductor chip. This array technology has been used for applications in genetic analysis, RNAi drug discovery, biodefense applications, chemical sensing, and nanomaterials discovery. This collaboration seeks to expand the applicability of this technology for the synthesis of diverse molecular libraries.

Professor Moeller commented, "While the technological advantages of CombiMatrix`s semiconductor based microarrays are obvious, this research will define the full range of synthetic chemistry that can be accomplished on an electrochemically addressable chip thereby allowing us to take full advantage of chip-based molecular screening methods in the future."

"This is yet an additional application of our arrays in the nanotechnology field," said Dr. Amit Kumar, President and Chief Executive Officer of CombiMatrix. "We have internally demonstrated synthesis of numerous nucleic acids, peptides and other non-biological chemicals on our arrays, and this collaboration will expand that work to include additional chemicals by adapting both well known and entirely new chemical reactions for use on CombiMatrix`s unique chip platform. The funding provided by the NSF provides validation for this work."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix`s technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand.

CombiMatrix`s Express Track(SM) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. The initial focus of Express Track(SM) includes the following viral diseases:

Virus Collaborator

SARS NIAID/USAMRIID

HIV type 1 irsiCaixa-Dr. Bonaventura Clotet

HIV type 2 To Be Announced

West Nile virus To Be Announced

Human Papillomavirus type 16 To Be Announced

Human Herpes 8 (Kaposi`s sarcoma) To Be Announced

Smallpox (Variola) To Be Announced

Influenza virus A To Be Announced

Influenza virus B To Be Announced

Hepatitis C To Be Announced

CombiMatrix is also establishing applications of its arrays
through other partnerships as follows:

Project Collaborator

Cancer Diagnosis (Lymphoma) University of Washington/Rational
Diagnostics

RNA Drug Targets Professor Gregory L. Verdine,
Harvard University

Parasite

Leishmania Seattle Biomedical Research Institute

Trypasonoma Seattle Biomedical Research Institute

The Acacia Technologies group licenses its Digital Media Transmission (DMT) technology to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 31 foreign patents.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[Gluewuermchen]

Vorbörslich bereits 6 % im plus

[Gluewuermchen]

Bin ich eigentlich der einzige der investiert ist??

Habe heute nochmals nachgekauft!

[Gluewuermchen]

News...
Bald werden die ersten Empfehlungen kommen!
Noch kann man einsteigen!

Press Release Source: Acacia Research Corporation

CombiMatrix to Webcast Presentation at the U.S. Bankcorp Piper Jaffray Health Care Conference
Wednesday January 21, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 21, 2004--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that Dr. Amit Kumar, President and CEO of CombiMatrix, will present an overview of the Company at the U.S. Bankcorp Piper Jaffray Health Care Conference at the Pierre Hotel in New York City.

A live transmission of the presentation will take place at 11:00 am ET on Thursday, January 29, 2004. An archived webcast will be available for 30 days. To access the live webcast or archived presentation, please go to www.combimatrix.com/news_events.htm.

About Acacia Research Corporation

Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix`s technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand.

CombiMatrix`s Express Track(SM) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. The initial focus of Express Track(SM) includes the following viral diseases:

-0-

Virus Collaborator

SARS NIAID/USAMRIID
HIV type 1 irsiCaixa-Dr. Bonaventura Clotet

HIV type 2 To Be Announced
West Nile virus To Be Announced
Human Papillomavirus type 16 To Be Announced
Human Herpes 8 (Kaposi`s sarcoma) To Be Announced
Smallpox (Variola) To Be Announced
Influenza virus A To Be Announced
Influenza virus B To Be Announced
Hepatitis C To Be Announced

CombiMatrix is also establishing applications of its arrays
through other partnerships as follows:

Project Collaborator

Cancer Diagnosis (Lymphoma) University of Washington/Rational
Diagnostics
RNA Drug Targets Professor Gregory L. Verdine,
Harvard University
Parasite

Leishmania Seattle Biomedical Research
Institute
Trypasonoma Seattle Biomedical Research
Institute


The Acacia Technologies group licenses its Digital Media Transmission (DMT) technology to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[Gluewuermchen]

Leute,ich habe es euch gesagt!

CBMX explodiert!

[bavarianzock]

sieht fast so aus, als hättest du recht, glühwürmchen

[Gluewuermchen]

http://www.businessweek.com/investor/list/wall_toc01.htm


Der Grund des heutigen Anstieges!

Ich würde jeden Pullback zum Kauf nutzen!

[proFEiT]

Glühwürmchen,
Du bist der Hammer der uns alle reich macht!

[Gluewuermchen]

Meinst Du..

Würd mich für euch freuen

[Gluewuermchen]

Noch ein paar Infos zu combimatrix


Mukilteo firm on cutting edge of Homeland defense work

Combimatrix also working to cure world`s diseases

Paul Archipley

While all the recent press coverage and water cooler chat has been about Boeing, companies like Combimatrix Corporation may hold the key to Snohomish County`s long-term economic health.
Headquartered in Mukilteo, Combimatrix hosted Sen. Patty Murray and state and local officials last week to tout its biotechnical advances and their current and future applications.
Snohomish County and the rest of the Puget Sound has a growing biotech industry that could help secure good jobs for decades to come.
Certainly, the varied attractions of the Northwest – from climate to lifestyle to economic opportunities – are playing a part in the draw. According to Combimatrix president and CEO Dr. Amit Kumar, one of the reasons for their move from California in 1999 was to afford employees an opportunity to own homes.
And moving to a region where biotech is a fast-growing sector helps create a snowballing effect that benefits all. When Combimatrix arrived, it had 10 employees. That number is close to 70 today, and it`s still hiring.
In addition, it is engaged in collaborative efforts with other local companies, as well as the University of Washington.
That`s a good sign for the region`s future economic health.
But it`s human health around the world that may benefit most from the research and development going on at Combimatrix.
The company is coupling advances in biotechnology with gains in computer/electronics to develop products that may one day help cure difficult illnesses like leukemia.
In addition, Combimatrix is addressing terrorist threats with development of Homeland security products that detect dangerous biological agents in the air we breathe.
According to Dr. David Danley, director of Homeland Security and Defense Programs at Combimatrix, the company is developing palm-sized instruments that can quickly and cheaply identify biological agents on the battlefield, giving soldiers an opportunity to don protective clothing.
For the civilian population, the firm is developing smoke detector-sized instruments that continuously test the atmosphere in office buildings, subways and other gathering places where terrorists might release bioweapons.
A key, said Dr. Kumar, is advances in gene sequencing. He noted a researcher in the 1980s would spend months analyzing a single AIDS gene.
"Twenty years ago, a researcher would`ve taken a year to analyze one gene," Kumar said. "Today, a researcher can analyze a thousand genes in one day."
And in the `90s, the "decade of sequencing," biotechnical and semiconductor advances enabled researchers to sequence entire genomes in relatively short periods, he noted.
The SARS genome, for example, was sequenced last April by the international community just months after its outbreak.
Of course, intense R&D is expensive, so companies like Combimatrix need to develop products – and partnerships – that will benefit its bottom line as well as mankind.
Thus, for every system it develops to benefit military needs, such as anthrax or smallpox detection, Combimatrix looks for broader applications in the private sector.
"As a small company, we have to focus on commercial opportunities, such as in health care," Kumar said.
"And companies like ours couldn`t do it without connections to larger military defense contractors."
The importance of companies like Combimatrix to the Northwest isn`t lost on public officials, either.
Sen. Murray, pledging her support in Washington, D.C., said, "It strikes me how much money you have to put into research and development to produce a product that others can buy cheap.
"I`m delighted to be a part of that effort."
And Murray complimented the workers at the Mukilteo headquarters for the valuable work they do.
"I`m sure you`re going to make a difference in people`s lives," she said. "I`m really glad you`ve chosen Washington state."

Have an opinion? Tell Mukilteo what’s on your mind. Email letters to the editor,

[Gluewuermchen]

CombiMatrix: Revolutions, Coming Soon to a Microarray Near You


12/15/03—Acacia Research`s CombiMatrix Group says it is set to launch CustomArray, a fully customizable DNA microarray platform, in March 2004. These semiconductor-based arrays (approx. 1cm2) are integrated on a standard 1-inch x

3-inch slide format and contain in-situ synthesized oligonucleotides, prepared using CombiMatrix`s patented virtual flask technology. Initially, CustomArrays will be offered with 1,000 sites per 1cm2. CombiMatrix anticipates upping that number to 13,000 sites per 1cm2 by 2Q 2004.

According to the company, customers can choose to design their CustomArray around any genome, any genes or probe sequences, and with oligonucleotides of any length. Customers will also have the ability to incorporate multiple genomes and oligonucleotide lengths on the same chip, all with no upfront subscription, special equipment, or design fees. CustomArrays require standard hybridization techniques and can be read with most commercial fluorescent detection reader systems.

[nanoplay]

Bei all deiner Freude aber bitte mach nicht jeden Tag einen neuen Thread auf für die gleiche Aktie!

Es wird immer unübersichtlicher hier!!!

[Gluewuermchen]

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Nov. 6, 2003--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix Group will launch CustomArray(TM), the first fully customizable DNA microarray platform, in the first quarter of 2004. A select group of beta customers will be provided CustomArray(TM) products in the 4th quarter of 2003, and these products will be available to the worldwide life sciences community in March 2004.

"The CustomArray(TM) microarray platform provides fast turnaround of new, custom designed microarrays allowing users to maintain critical research momentum," said Dr. Amit Kumar, President and CEO of CombiMatrix. "Flexibility to change array content rapidly will support pharmaceutical, biotechnology and diagnostic companies to more efficiently identify, assess, and validate new drug candidates or biological markers for further development."

CustomArrays(TM) are semiconductor based arrays (approx. 1cm2) integrated on a standard 1" x 3" slide format. CustomArrays(TM) contain in-situ synthesized oligonucleotides, prepared using CombiMatrix`s patented virtual flask technology. CustomArrays(TM) require standard hybridization techniques and can be read with most commercial fluorescent detection reader systems. CustomArrays(TM) will initially be offered with 1,000 sites followed by 13,000 sites per 1cm2, anticipated to be released in the 2nd quarter of 2004. CombiMatrix custom arrays can be delivered to customers within a few days.

Customers will have the ability to order fully customizable arrays in quantities as small as a single array.

CustomArray(TM) features the following unique characteristics:

* No upfront subscription, special equipment, or design fees
* Any genome (over 1,100 organisms have been sequenced)
* Any genes or probe sequences
* Oligonucleotide lengths of choice
* Multiple genomes on the same chip
* Multiple oligonucleotide lengths on the same chip
* Many other customizable parameters are also available

In addition to the CustomArray(TM) platform, CombiMatrix will also offer a series of catalog arrays.

Customers will have access to CombiMatrix`s suite of software applications for probe design, probe layout, and data extraction. Target Specifier(TM) software allows the user to specify lists of probes that will be built on an array. The user can drag and drop files to specify lists of their own custom probes. They can also specify lists of genes for which they would like probes designed, and the Probe-Design System(TM) will automatically design probes according to various user-selected parameters such as length and melting temperature. Layout Designer(TM) software allows the customer to put probes where they want on an array, or the system can lay out probes automatically. Microarray Imager(TM) software allows a customer to extract a spreadsheet of data from an array image.

In the future, CombiMatrix will make available desktop array synthesizers for sites that want in-house array production capability.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix`s technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand.

CombiMatrix`s Express Track(sm) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. The initial focus of Express Track(sm) are the following viral diseases:

Virus Collaborator
SARS NIAID/USAMRIID
HIV type 1 irsiCaixa -- Dr. Bonaventura Clotet

HIV type 2 To Be Announced
West Nile virus To Be Announced
Human Papillomavirus type 16 To Be Announced
Human Herpes 8 (Kaposi`s sarcoma) To Be Announced
Smallpox (Variola) To Be Announced
Influenza virus A To Be Announced
Influenza virus B To Be Announced
Hepatitis C To Be Announced

CombiMatrix is also establishing applications of its arrays through other partnerships as follows:

Project Collaborator
Cancer Diagnosis (Lymphoma) University of Washington/Rational
Diagnostics

Parasite
Leishmania Seattle Biomedical Research Institute
Trypasonoma Seattle Biomedical Research Institute

The Acacia Technologies group licenses its Digital Media Transmission ("DMT") technology to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com.

[Gluewuermchen]

@nanoplay

werde diesen Thread weiterführen

no sweat!

[Dirac]

@Glühwuermchen:

Jetzt gibt es schon 4 verschiedene threads über Combimatrix hier bei WO. Wir sollten uns nicht verzetteln und uns auf einen konzentrieren.

Grüße Dirac

[Dirac]

Ich stell nochmal den letzten Beitrag aus meinem Thread hier rein:

Hier noch ein Bericht über CombiMatrix aus der neuesten Ausgabe von BusinessWeek-online vom 26.01.2004


INSIDE WALL STREET
By Gene G. Marcial


Why CombiMatrix Is Going Gaga Over Nano

Nanotech is the Street`s latest buzzword. Technology Review, put out by Massachusetts Institute of Technology, calls it the key materials technology for this century, capable of altering the performance of drugs, chemicals, and computers. So investors are chasing nano stocks. Enter CombiMatrix (CBMX ) (CBMX), whose stock climbed from 3 in mid-December to 5.39 on Jan. 14.

First featured in this column on Feb. 3, 2003, at 2.90, CombiMatrix makes micro-biochips that perform DNA diagnostics and detect hazardous chemicals. In December, the U.S. Army inked a pact with CombiMatrix to develop microchips for detecting hazardous biotech agents. CombiMatrix` partner, Nanomaterials Discovery, has just agreed to use CombiMatrix` biochips to develop fuel cells, rechargeable lithium batteries, and phosphors for flat-panel displays.

Jonathan Aschoff of Brean Murray says Nanomaterials Discovery has a patent on using its own technology and CombiMatrix` biochips to discover new nanomaterials. Aschoff, who rates CombiMatrix a strong buy , says its microchips shorten the discovery process. Aschoff has a 12-month target of 8, expects the company to turn profitable this year, with earnings of 45 cents a share


Profitable Nanotech-Gesellschaften gibt es nicht gerade viele!!

Grüße Dirac

[Gluewuermchen]

Ja,wir können bei einem Thread bleiben,kein Thema!

Hatte meinen am 20.1.eröffnet,war glaub ich der erste

überhaupt über diese Aktie!

Werde in dem hier weiter posten um Informationen zu declarieren!

gruss glüh

[Gluewuermchen]

heute + 7 % mal wieder!

Vielleicht aufgrund der Teilnahme am Montag!

VERSION 1
INVEST NORTHWEST 2004
MONDAY, MARCH 22
7:00 AM - 7:50 AM Registration/Breakfast
7:50 AM – 8:10 AM SOUND ROOM
Welcoming Remarks
8:20 AM – 9:40 AM
BAY AUDITORIUM
Genomics
8:20 CombiMatrix
8:40 Epoch Biosciences
9:00 Virogenomics
9:20 Znomics
HARBOR DINING ROOM
Cardiovascular
8:20 Cardiome Pharma
8:40 Inovise Medical Technologies
9:00 Pathway Medical
9:20 Quinton Cardiology Systems
9:40 AM – 10:00 AM Break
10:00 AM - 11:00 AM
BAY AUDITORIUM
Cancer Therapy
10:00 AnorMED
10:20 Biomira
10:40 Cell Therapeutics
HARBOR DINING ROOM
Respiratory
10:00 Corus Pharma
10:20 Inologic
10:40 Spiration
11:00 AM – 12:00 PM
BAY AUDITORIUM
Infectious Disease
11:00 Cytovax Biotechnologies
11:20 ID Biomedical
11:40 Stressgen Biotechnologies
HARBOR DINING ROOM
Drug Delivery
11:00 Celator Technologies
11:20 Nastech Pharmaceutical
11:40 QLT
12:00 PM – 1:50 PM Lunch and panel discussion: Best Practices For Making Deals Happen (Jack
Anthony, Senior VP, Tularik and Arlene Morris, President & CEO, Affymax)
2:00 PM – 3:00 PM
BAY AUDITORIUM
Inflammation & Hematology
2:00 ICOS
2:20 Inflazyme Pharmaceuticals
2:40 ZymoGenetics
HARBOR DINING ROOM
Cancer Therapy
2:00 CEPTYR
2:20 OncoGenex Technologies
2:40 Receptor BioLogix
3:00 – 3:20 PM Break
3:20 PM – 4:40 PM BAY AUDITORIUM
Central Nervous System
3:20 Ability Biomedical
3:40 NeuroMed Technologies
4:00 ProteoTech
4:20 Sound Pharmaceuticals
HARBOR DINING ROOM
Cancer Devices & Diagnostics
3:20 Calypso Medical
Technologies
3:40 EpiGenomics
4:00 Tessera Diagnostics
4:20 Xillix Technologies
4:40 PM – 5:20 PM BAY AUDITORIUM?
Keynote speech: Richard Klausner, Executive Director, Global Health, The Bill &
Melinda Gates Foundation
5:30 PM – 7:30 P.M. Invest Northwest Reception - International Promenade
VERSION 1
INVEST NORTHWEST 2004
TUESDAY, MARCH 23
7:00AM –
7:50AM
Registration/Breakfast
7:50AM –
8:50AM
INTERNATIONAL PROMENADE
Panel: Tales Of Serial Entrepreneurship (Bruce Carter, President & CEO, ZymoGenetics;
Donny Strosberg, President & CEO, Hybrigenics; and Christopher Henney, Chairman, Dendreon)
9:00AM –
10:00AM
BAY AUDITORIUM
Cancer Therapy
9:00 Trubion
Pharmaceuticals
9:20 Twinstrand
Therapeutics
9:40 Xcyte Therapies
HARBOR DINING ROOM
Bioinformatics
9:00 Geospiza
9:20 TeraNode
9:40 VizX Labs
SOUND CONF. ROOM
Devices
9:00 ARC
Pharmaceuticals
9:20 Light Sciences
9:40 LipoSonix
10:00AM–
10:20AM
Break
10:20 AM–
11:20 AM
BAY AUDITORIUM
Cancer Therapy
10:20 NeoRx
10:40 Seattle
Genetics
11:00 Sonus
Pharmaceuticals
HARBOR DINING ROOM
Infectious Disease
10:20 Illumigen
Biosciences
10:40 International
Therapeutics
11:00 Koronis
Pharmaceuticals
SOUND CONF. ROOM
Gene Delivery & Expression
10:20 Chromos
Molecular Systems
10:40 Protiva
Biotherapeutics
11:00 Targeted
Genetics
11:20 AM–
12:20 PM
BAY AUDITORIUM
Cancer Therapy
11:20 Corixa
11:40 Dendreon
12:00 Oncolytics
Biotech
HARBOR DINING ROOM
Drug Discovery
11:20 Cytopeia
11:40 PhenoGenomics
12:00 Xenon Genetics
SOUND CONF. ROOM
Devices
11:20 Clear Medical
11:40 Micronics
12:00 SonoSite
12:20 PM –
2:30 PM
INTERNATIONAL PROMENADE
Lunch and panel: Life Sciences Financing: The Pathology of Bubbles and Windows (George
Milstein, Senior Managing Partner, Pacific Growth Equities; Rod Ferguson, Managing Director,
JPMorgan Partners; Deepa Pakianathan, Partner, Delphi Ventures; Joseph Eichinger, VP,
Finance, Therus; and Michelle Burris, CFO, Corixa)
2:30 PM – 5:00
PM
Networking for CEOs and investors only

[Gluewuermchen]

Combimatrix macht heute wieder richtig Spass!

[Gluewuermchen]

Und hier der Grund..

09:32 ET CBMX target raised to $10 at Brean Murray 7.60 +0.23: Brean Murray reiterates its Strong Buy on CombiMatrix and raises its target to $10 from $8. The firm believes the co`s landscape has recently changed for the better, thereby leading it to reduce its 2006 EPS discount rate to 25% from 35% which results in the new target price. The 35% discount rate is no longer justified, as earlier uncertainties of Roche`s launch timeline for matrixArray are no longer relevant. CBMX is now in control of the entire launch process, which should commence in March 2004.

[Gluewuermchen]

Scheint vor der Konferenz am Donnerstag richtig abzugehen!

close @ 8,52

unglaublich

[Gluewuermchen]

I love this stock


Press Release Source: Acacia Research Corporation

CombiMatrix Announces First Commercially Available Microarray for ``Bird Flu`` Influenza A Virus
Thursday January 29, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 29, 2004--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has made commercially available the first microarray designed for the H5N1 "Bird Flu" influenza A virus.

The World Health Organization (WHO) appealed Tuesday, Jan. 27th for technical assistance and expert advice to help stop the threat to humans and agriculture posed by this virus. CombiMatrix utilized its proprietary probe-design software and ability to rapidly synthesize novel DNA microarrays to respond within two days.

CombiMatrix`s microarray allows for the identification of the H5N1 virus, and importantly, also allows the tracking of mutations that can occur in its genetic makeup as it goes through patterns of bird and human infection.

Bird Flu is a member of the influenza A virus family, the same family responsible for the 1918 influenza pandemic, which killed 20-40 million people. According to Dr. Amit Kumar, President and CEO of CombiMatrix, "Mutations in the genetic makeup of this family of influenza viruses have in the past greatly affected infectiousness and lethality of individual strains. Our microarray, with its ability to help track such mutations, may be of assistance in dealing with this virus and its impact upon public health. Similar to our efforts with the SARS virus, this new array demonstrates our ability to rapidly respond to emerging diseases."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix`s technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand.

CombiMatrix`s Express Track(sm) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. The initial focus of Express Track(sm) includes the following viral diseases:

Virus Collaborator
----- ------------
SARS NIAID/USAMRIID
HIV type 1 irsiCaixa-Dr. Bonaventura Clotet

HIV type 2 To Be Announced
West Nile virus To Be Announced
Human Papillomavirus type 16 To Be Announced
Human Herpes 8 (Kaposi`s sarcoma) To Be Announced
Smallpox (Variola) To Be Announced
Influenza virus A To Be Announced
Influenza virus B To Be Announced
Hepatitis C To Be Announced

CombiMatrix is also establishing applications of its arrays through
other partnerships as follows:

Project Collaborator
------- ------------
Cancer Diagnosis (Lymphoma) University of Washington/
Rational Diagnostics
RNA Drug Targets Professor Gregory L. Verdine,
Harvard University

Parasite
--------
Leishmania Seattle Biomedical Research Institute
Trypasonoma Seattle Biomedical Research Institute


The Acacia Technologies group licenses its Digital Media Transmission (DMT) technology to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 31 foreign patents.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[Gluewuermchen]

Vorbörslich 9,07 $

ohne worte!

[Dirac]

Der Anstieg kommt mir mittlerweile schon etwas übertrieben vor, oder...?





Gruß Dirac

PS. Ich warte auf einen Rücksetzer, um noch mal aufzustocken.

[Gluewuermchen]

Sie ist super gelaufen!
Ich denke sie wird auch weiter laufen!
25 mill. Aktien nur draussen!

Von heute!

Top-Tipp des Tages

Nach den starken Zahlen von Branchenkollege AFFYMETRIX müssen Sie nun unbedingt auch wieder COMBIMATRIX ins Auge fassen, die als kleiner David im Biochip-Markt dem Überkonkurrenten AFFYMETRIX erfolgreich Paroli bietet und den wir Ihnen schon im Frühsommer letzten Jahres im Detail vorgestellt hatten! Auch wenn unsere Erwartungen hier zunächst mit einem sehr langen Vorlauf einer Geduldsprobe unterzogen wurden, beginnt sich die Story jetzt mit Zeitverzögerung perfekt zu entwickeln. Der agile kleine Player meldete vor wenigen Tagen, mit der Armee einen Kooperationsvertrag zur Entwicklung Nachweisverfahren für bestimmte biologische Substanzen abgeschlossen zu haben – es geht also einmal mehr um das Thema Bio-Defense und damit einen Markt, den es vor wenigen Jahren in dieser Form und Größenordnung wie heute gar nicht gab. Aber der Reigen geht weiter: Wie am Schnürchen kommen da momentan gute News von COMBIMATRIX rüber mit der Patentanmeldung für die DMT-Technologie in 14 europäischen Ländern, für die bereits ein massive Lizenzgeschäft in den USA anzulaufen beginnt, mehreren Kooperationsabkommen mit Universitäten und dem Milestone-Payment vor Weihnachten von dem Partner TOPPAN, der gut USD 1,25 Mio. in die Kassen spülte. Der Kurs reagiert jetzt entsprechend: Von Kursen um USD 3 zum Jahresbeginn schossen die Papiere zuletzt auf neue Jahreshochs von USD 8,75 davon, gestern allein mit weiteren 10% Plus. Und das hat gute Gründe: Nach den Konsensforecasts der Analysten steht für COMBIMATRIX für das laufende Jahr der Break-Even zu erwarten mit Gewinne bis knapp 50 Cents je Aktie nach noch Verlusten bis 75 Cents je Aktie in 2003. Zieht man die Dynamik der neuen Zahlen von AFFYMETRIX bei der Betrachtung mit ein, sollten die Schätzungen für 2004 nun eher die Untergrenze der anzuvisierenden Range sein. Das heißt: Zu laufenden Kursen wird der Titel gerade mal mit einem KGV von 16 bezahlt, was für ein – dann – profitables und extrem wachstumsstarkes Biotech-Unternehmen wirklich nur ein schlechter Witz ist. Die Market Cap liegt jetzt bei 172 Mio. USD – damit kommen jetzt erst nach den kräftigen ersten Sprüngen auch Käufe von Fonds in Betracht, die sich diese Perle kaum entgehen lassen werden. Sofern Sie die Position im letzten Jahr zu früh geräumt hatten, stellen Sie jetzt sofort wieder einen Fuß in die Tür! WKN 164 630

Daily News/30.Januar 2004

[Gluewuermchen]

Der nächste Hammer

Wird ja immer besser!

Press Release Source: Acacia Research Corporation

CombiMatrix Names Nanotechnology Leader F. Mark Modzelewski to Its Scientific Advisory Board
Monday February 2, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb. 2, 2004--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has named F. Mark Modzelewski to its Scientific Advisory Board. Mr. Modzelewski is the founder and Executive Director of the Nanobusiness Alliance (www.nanobusiness.org).

Mr. Modzelewski is also a member of the Nanotechnology Technical Advisory Group to President Bush`s Council of Advisors on Science and Technology (PCAST), was recognized by Forbes magazine as one of nanotech`s 5 "powerbrokers," and he has testified before the U.S. Senate on nanotechnology funding, investment, technology transfer and global competition.

Mr. Modzelewski has taught classes on the business of nanotechnology at Northwestern`s Kellogg School and NYU`s Stern School of Business, and he has lectured before numerous global technology and investor conferences, leading think tanks, as well as briefing the White House, US Dept. of Commerce, NSF, Congress, the Federal Reserve`s Financial Markets retreat, global Fortune 500 companies, and numerous foreign government agencies. He has been featured in Time, Newsweek, US News, ABC News, CNBC, CNNfn, BBC, Bloomberg Radio, Forbes, Business Week, Fortune, Wall Street Journal, and Investors Business Daily.

He has also held positions at various firms including Opion, Niehaus, Ryan, Wong NYC, and Golin/Harris International. Before entering the private sector, he was an appointee in the Clinton Administration, where he served as Special Assistant to Sec. Henry Cisneros at HUD and Sec. Dan Glickman of USDA. Mr. Modzelewski is a graduate of the University of Denver College of Law and Boston University.

"I am impressed with CombiMatrix`s technology and capabilities in the nanotechnology space, as well as its broadly encompassing strategy for commercialization of its core technology into multiple markets. I am looking forward to working with the company in the future," said Mr. Modzelewski.

"Based on Mr. Modzelewski`s accomplishments, one can say that he is truly a visionary in the nanotechnology field," said Dr. Amit Kumar, President and CEO of CombiMatrix. "We are pleased to have him join us and provide guidance and advice as we continue to build CombiMatrix into one of the leaders in the fields of biotechnology and nanotechnology."

[Gluewuermchen]

Das muss man sich mal überlegen,den Gründer der

Nanobusiness.org

Allein die connections in finanzieller Hinsicht!

[Gluewuermchen]

Hier der Link zur Nanobusiness.org

CBMX wird noch ein richtig einschlagen,da bin ich von überzeugt!

http://www.nanobusiness.org/

[Gluewuermchen]

CBMX schliesst nach dem letzten Anstiegen nun mal im Minus!
Werd morgen direkt nachkaufen!

gruss

[Gluewuermchen]

Habe heut nochmal nachgekauft zu 5,7 €

denke war eine gute Gelegenheit!

gruss

[Gluewuermchen]

Press Release Source: Acacia Research Corporation

CombiMatrix to Webcast Presentation at the Roth Capital Partners 16th Annual Growth Stock Conference
Tuesday February 3, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb. 3, 2004--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that Dr. Amit Kumar, President and CEO of CombiMatrix, will present an overview of the Company at the Roth Capital Partners 16th Annual Growth Stock Conference at the St. Regis Monarch Beach Resort & Spa, located in Dana Point, California.

A live transmission of the presentation will take place at 2:30 p.m. PT on Tuesday, February 17, 2004. An archived webcast will be available for 30 days. To access the live webcast or archived presentation, please go to www.combimatrix.com/news_events.htm.

[poponase]

@ gluehwürmchen

damitDu nicht immer nur alleine schreibst und denkst es wäre keiner bei dieser Aktie investiert, will ich erstmal hallo sagen und mich füer die immer aktuellen Nachrichten, die Du hier reinstellst danken.
Bin auch sehr von der Aktie überzeugt

gruß

Poponase

[Gluewuermchen]

Hallo popnase(*gg*)

Freut mich,ich hoffe wir machen schöne Gewinne zusammen!

Vielleicht werden ja noch andere mit einsteigen ins Boot!

gruuss glüh

[Gluewuermchen]

NAZ down
CBMX up

[Gluewuermchen]

+8%



unglaublich

[poponase]

Hi Gluehwürmchen,

also mich stört das ehrlichgesagt gar nicht, dass sich andere nicht für den Wert interessieren, denn wir sind nicht von Deutschland abhängig. Das Einzige was zählt ist, dass die Amis wissen was gut ist

Mir ist allerdings nicht entgangen,. dass wir trotzdem der Markt heute abwärts ging im Plus geschlossen haben.

Gruß

Poponase

[Gluewuermchen]

Combi zieht an in USA!

[Gluewuermchen]

7,80 $

Starke Käufe momentan!

Hmm,

[poponase]

Hoffe unser Teil springt heute noch mehr an und es gibt bald wieder news zu vermelden.

Gruß

Poponase

PS: Bei W-online sind wir Eizelkämpfer während bei Nano Invests die Aktie viele kennen. Mir aber egal

[Gluewuermchen]

Ja,poste dort ja auch und hab mich dort als Moderator eintragen lassen!

Ich denke es kommen News,der heutige Tag war nicht normal!






Schau Dir mal die Käufe um 12 mittags an!Ziemlich hohes Volumen!

gruss glüh

[Gluewuermchen]

Immer wieder Hammernews!



Press Release Source: Acacia Research Corporation

CombiMatrix`s Partner Nanomaterials Discovery Corporation Issued Key Nanotech Patent
Wednesday February 11, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb. 11, 2004--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group`s joint product development partner, Nanomaterials Discovery Corporation (NDC), has been granted U.S. Patent No. 6,683,446, entitled "Electrode array for development and testing of materials," ("the `446 patent"). CombiMatrix and NDC will share revenues on sales of new materials and tools under a Joint Product Development and License Agreement.

"The development of new nanostructured materials for commercial applications has traditionally been a cumbersome process," said Dr. Don Montgomery, President and CEO of NDC. "Electrochemistry offers the most comprehensive, reproducible and well-vetted approach to developing new nanostructured materials. The methods disclosed in the `446 patent allow us to accelerate the pace of discovery of new nanomaterials by a factor of over a thousand when compared to traditional approaches."

"We are encouraged by the issuance of this patent and we look forward to a productive relationship under our collaboration," said Dr. Amit Kumar, President and CEO of CombiMatrix. "We expect the new nanotechnology initiatives sponsored by the Federal Government will help emerging nanotech companies develop innovative technology and new products."

NDC has a long-standing research partnership with the University of Wyoming that has focused on using electrode arrays to search for new catalysts for fuel cells, new cathode materials for rechargeable lithium batteries, and new phosphors for flat panel displays. The partnership has received substantial funding from the Office of Naval Research, Department of Energy, and the National Science Foundation.

About Nanomaterials Discovery Corporation

NDC combines the power of nanotechnology with the high-throughput preparation and screening capabilities of combinatorial chemistry to develop and refine new nanostructured materials. Founded by The Blue Sky Group Inc. of Laramie, Wyoming in 2003, NDC has partnered with CombiMatrix Corporation of Washington. More information is available on the web at www.nanomaterialsdiscovery.com.

About Acacia Research Corporation

Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix`s technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand.

CombiMatrix`s Express Track(SM) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. The initial focus of Express Track(SM) includes the following viral diseases:

Virus Collaborator

SARS NIAID/USAMRIID
HIV type 1 irsiCaixa-Dr. Bonaventura
Clotet

HIV type 2 To Be Announced
West Nile virus To Be Announced
Human Papillomavirus type 16 To Be Announced
Human Herpes 8 (Kaposi`s sarcoma) To Be Announced
Smallpox (Variola) To Be Announced
Influenza virus A To Be Announced
Influenza virus B To Be Announced
Hepatitis C To Be Announced

CombiMatrix is also establishing applications of its arrays
through other partnerships as follows:

Project Collaborator

Cancer Diagnosis (Lymphoma) University of
Washington/Rational
Diagnostics

RNA Drug Targets Professor Gregory L.
Verdine, Harvard
University

Parasite

Leishmania Seattle Biomedical
Research Institute

Trypasonoma Seattle Biomedical
Research Institute

The Acacia Technologies group licenses its Digital Media Transmission (DMT) technology to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 31 foreign patents.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

[Gluewuermchen]

Also,wenn die Companie keinen Spass bringen wird!

[Gluewuermchen]

Premarket +7 %

8,34 $

[Gluewuermchen]

Press Release Source: Acacia Research Corporation

Acacia Research to Release Fourth Quarter Financial Results and Host Conference Call
Thursday February 12, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb. 12, 2004--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today it will release its fourth quarter financial results on Thursday, February 19, 2004. Results will be released at the close of trading on the NASDAQ national market.

A conference call is scheduled for the same day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern). Paul R. Ryan, Chairman and CEO of Acacia Research, Robert "Chip" Harris, President, and Amit Kumar, Ph.D., CEO of CombiMatrix Corporation will host the call.

The CombiMatrix Group presentation and Q&A will precede the Acacia Technologies Group presentation and Q&A session.

To listen to the presentation by phone, dial [phone] for domestic callers and [phone] for international callers. A replay of the audio presentation will be available for 30 days at [phone] for domestic callers and [phone] for international callers, both of whom will need to enter the code 337810 when prompted.

[Gluewuermchen]

Bullische Formation!

http://www.stockta.com/cgi-bin/analysis.pl?symb
=CBMX&num1=5&cobrand=&mode=stock" target="_blank" rel="nofollow ugc noopener">http://www.stockta.com/cgi-bin/analysis.pl?symb
=CBMX&num1=5&cobrand=&mode=stock

[Gluewuermchen]

Werd heut nochmal nachkaufen,nächste Woche kommen die Zahlen
und der Chart sieht mir nach 2 stelligen Kursen aus!

Viel Spass

[JuppSchmitz]

Hallo Leute,

so einsame Einzelkämpfer seit Ihr nun auch nicht.

Über dieses Unternehmen wird bereits seit 2000 hier im Board geschrieben. Damals hies das Unternehmen nur ACACIA RESEARCH.
Zwischenzeitlich wurde es gesplittet und zwar in CBMX und ACTG.

Ihr solltet Euch ACTG auch mal anschauen. Die haben mindesten das gleiche Potential.

Ich wünsche Euch noch einen schönen Rest vom Sonntag.

Jupp

[NOBODY_III]

Nachzügler kaufen umgehend (17.02.2004)


Vor genau einem Jahr hat „Global Biotech Investing“ die damals just von Acacia Research ausgegliederte Combimatrix (WKN 164630) als Geheimtipp zum Kauf empfohlen. Seitdem stieg der Kurs um 300 Prozent – und hat dennoch nur ein KGV von 16:

Das junge Biochip-Technologie-Unternehmen hat mit einer Gewinnerwartung von 0,50 US-Dollar im laufenden Geschäftsjahr nicht nur den Breakeven, sondern beim aktuellen Kurs von 8 US-Dollar ein KGV von gerade 16. Dies ist den Redakteuren wesentlich zu wenig, zumal Combimatrix sich einen Nanotech-Experten ins Unternehmen geholt, der zum Beratergremium des US-Präsidenten gehört. Vor diesem Hintergrund halten sie es für möglich, dass Combimatrix künftig noch leichter an Forschungs- und Entwicklungsaufträge und somit entsprechende Gelder gelangt.

Erst zuletzt wurden ein weiterer Biodefense-Auftrag von der US-Army sowie die Meilensteinzahlung eines Kunden bekannt gegeben, zu denen unter anderen Roche, die NASA und verschiedene Ministerien gehören. „Global Biotech Investing“ empfiehlt denjenigen, die noch Nachholbedarf haben, umgehend einige Aktien von Combimatrix ins Depot zu legen.

Quelle: "Global Biotech Investing"

ACACIA RESEARCH-COMB. 5.80 -3.33% 16.02.2004 - 10:30
(US0038812089; WKN 164630; AZG1)

[stawu]

Hallo!
Bin auch auf Combimatrix gestoßen.
Weiß jemand ob die Zahlen schon da sind und wie sie ausgefallen sind?
stawu

[Augustinus]

#49 stawu
Zahlen erschienen am 19.02. ,hab sie gelesen unter:
nasdaq.com

[Augustinus]

Auch unter nasdaq.com vom 23.02. ist zu lesen,
dass sie mit der Case Western Reverse University
zwecks Diagnostic für die Alzheimer Krankheit zusammen-
arbeiten.

[Augustinus]

In USA heute immmerhin wieder 6,90 +11% !

[Augustinus]

Die heutige Meldung klingt ganz gut:
Acacia licenses Digital Media Transmission (DMT)
to the Walt Disney Co.

[Augustinus]

Heute wieder über 7 $ und ich wollte sie schon
unter meinem Stopp Loss von 6 $ verkaufen...

[Dirac]

Es gibt fast keine Umsätze hier in Deutschland.
Erst kommt man nicht rein in die Aktie, später komt man schlecht wieder raus.
Es ist ein Jammer!
Gruß Dirac

[Quadian]

CombiMatrix Awarded $5.9 Million Department of Defense Contract for Development Of Biowarfare Detection Technology
Monday March 8, 7:01 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 8, 2004--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix Group has received a two-year contract from the Department of Defense (DOD) that will provide $5.9 million to further the development of its microarray technology for the detection of biological threat agents.
Under previously funded programs with the Department of Defense, CombiMatrix demonstrated that its microarray could be multiplexed for the simultaneous detection of toxins, viruses, and bacteria using immunoassay and genomic analysis. Unique to this platform is "on chip" electrochemical detection, which eliminates the need for a complex and expensive optical system.

"We are pleased with the granting of this contract. The funding will enable us to advance our technology into a new commercial area for CombiMatrix," stated Dr. Amit Kumar, President and CEO of CombiMatrix Corporation. "We hope this is the beginning of a long-term relationship with the DOD."

The focus of the new contract will be the integration of CombiMatrix`s biotechnology with microelectronics and microfluidics and the development of an automated system with maximum flexibility and sensitivity for biothreat agents with reduced size and cost. Under an existing Cooperative Research and Development Agreement (CRDA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), CombiMatrix will seek to integrate its system against a broad range of requirements from portable hand held devices to larger industrial units. CombiMatrix`s integrated detection system will target potential threats such as Bacillus anthracis (Anthrax), Yersina pestis (plague), toxins, and other agents that could be used as bioweapons by terrorists and other enemies.

"Our goal is to develop a versatile detector system around assays that are recognized as the gold standards for agent identification," said Dr. David Danley, Director of Homeland Security and Defense Programs for CombiMatrix. "This program will demonstrate the power of our technology for identifying the presence of biothreat agents, infectious diseases and other environmental hazards."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix`s technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand.

CombiMatrix`s Express Track(SM) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. The initial focus of Express Track(SM) includes the following viral diseases:

Virus Collaborator

SARS NIAID/USAMRIID
HIV type 1 irsiCaixa-Dr. Bonaventura Clotet
HIV type 2 To Be Announced
West Nile virus To Be Announced
Human Papillomavirus type 16 To Be Announced
Human Herpes 8 (Kaposi`s sarcoma) To Be Announced
Smallpox (Variola) To Be Announced
Influenza virus A To Be Announced
Influenza virus B To Be Announced
Hepatitis C To Be Announced


CombiMatrix is also establishing applications of its arrays through
other partnerships as follows:


Project Collaborator

Cancer Diagnosis (Lymphoma) University of Washington/Rational
Diagnostics
RNA Drug Targets Professor Gregory L. Verdine,
Harvard University


Parasite

Leishmania Seattle Biomedical Research
Institute
Trypasonoma Seattle Biomedical Research
Institute

The Acacia Technologies Group develops, acquires, and licenses patented technologies. Acacia`s DMT technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems.

Acacia Research-Acacia Technologies (Nasdaq: ACTG - News) and Acacia Research-CombiMatrix (Nasdaq: CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.



--------------------------------------------------------------------------------
Contact:
Acacia Research Corporation
Bret L. Undem, 425-493-2293
Media Relations
Fax: [phone]

[Augustinus]

Deshalb eröffnete sie auch in den USA mit 7,10 $,
jetzt jedoch schon wieder auf 6,83 $ abfallend.

[brezlbua]

So langsam dürfte der Wert wieder interessant werden. Nach der ausgiebigen Korrektur, bei der die schwachewn Hände abgeschüttelt wurden (sieht man ja auch an der Resonanz hier) konnte sich bei rund 3,80 USD ein Boden bilden.

Die Zukunfts-Aussichten habe sich ja nicht verändert. Man sieht mal wieder: Aktien kauft man dann, wenn das Geschrei verstummt ist....

[Bienenvater]

Mittlerweile hat das Teil ja gewaltig korrigiert, das Interesse liegt nahe bei Null, nur 2 Besucher in diesem Thread heute.
Die Nano-Blase vom Januar ist vorbei. Ok. Aber ist diese Firma und sind ihre Aussichten denn so schlecht? Bin nicht investiert, habe den Schein aber seit Jan. auf meiner Watchlist.
Bevor ich ihn dort lösche, wollte ich hier noch einmal Meinungen sondieren. Vielleicht ist ja noch jemand investiert und auf dem Laufenden.
Danke
Bienenvater

[Bienenvater]

hm....haben heute 19 hier reingeguckt, - keiner hat einen Kommentar. Der Glühwurm scheint auch verglüht zu sein, war ja mal ganz euphorisch.

[xwin]

hallo. bin noch nicht in combimatrix investiert aber überlege nun ob ein einstieg sinnvoll ist. ich denke die aktie ist interessant. das produktportfolio und die partner überzeugen mich. ich hoffe das der boden nun gefunden wurde. die letzten nachrichten sind ja im mai erschienen. weiss jemand wann wieder mit neuen nachrichten zu rechnen ist?

danke

[brezlbua]

So langsam denke ich, kann man zugreifen. Wenn jetzt die Umsätze anziehen, ist der Wert schnell wieder bei 4,00 US-Dollar.
Hab mir deren Homepage mal genau angesehen. Das Produktportfolio ist erstklassig - mindestens so gut jedenfalls wie vor vier Monaten. Weitere Regierungaufträge liegen auch im Bereich des Möglichen.

[CyberCoach]

@56: Wenn ich das richtig lese, wollen die die Krankheiten diagnostizieren, die bei Starpharma Ltd. durch Einsatz von Dendrimeren demnächst verhindert, bzw. geheilt werden können. Frage: Ist Combimatrix am MIT im Soldier of Future Projekt angegliedert??????
Wenn ja, in welchen Disziplinen?

[xwin]

@all - warum steigt die Aktie schon seit drei Tagen? Gibt es Neuigkeiten?

Kennt jmd. den Link zu einem USA Board für diese Aktie?

Danke!!!

[yunior]

wurde am Dienstag vom Aktionär empfohlen deshalb.

[xwin]

@yunior - danke für die Info. Und dann steigt die zwei Tage lang? Ist doch aber auch in den USA stark gestiegen. Was hat sich denn an den Zukunftsaussichten verbessert?

Danke!

[Brokerprofi]

Ich glaube man hat einfach erkannt, das dies ein Nano-Play ist, der in den letzten Monaten viel zu stark korrigiert hat, denn in diesem Wert stimmt einfach alles:

Günstige Aktie (KGV) die in der Hype-Industie Naonotech zu Hause ist
Verbesserte Auftragslage (Connections zur Regierung) Auftrag vom Militär
Dazu kommt die Zusammenarbeit mit Roche (Financial Backing)

Für mich bedeutet das schlicht und einfach Strong buy - GO CBMX!!!

Mein Kursziel: 6 - 8 €

gruß
brokerprofi

[xwin]

hört man gerne. Bin vor drei Tagen eingestiegen. Offenbar war das ein guter Zeitpunkt

Hoffentlich taugt die auch für eine langfristige Anlage. Will nicht zocken damit.

[Brokerprofi]

Kurze Berichtigung: KGV ist noch negativ

[xwin]

sieht doch aber schön aus. Hoffe die Amis nehmen heute ihre Gewinne nicht mit. Der Wert sieht mir aber nicht wie ne Zockeraktie aus.

[Brokerprofi]

Nochmal zurück zum KGV.
Hier unterscheiden sich die Infos.

Consors reportet auf seiner Website ein positives KGV von 2004 bis 2007.

Yahoo reportet leicht negative earnings per share.
Letztendlich kommt es in einem Wachstmsmarkt darauf auch nicht an.

Wichtig ist es, Wachstum in einer attraktiven Branche vorweisen zu können. CBMX ist Biotech- und Nanotech mit solidem Hintergrund - und bietet ggf. im schwierigeren Umfeld (Ölpreise, Zinsen) eine Story die Anleger trotz allem zum Kauf bewegt.

[xwin]

ist jedenfalls ne sehr sehr interessante Kombination Nano- und Biotech. Wenn die die nächsten 3 Jahre überleben ist sicher noch sehr viel Raum nach oben im Kurs

[JuppSchmitz]

Kann jemand den Artikel aus dem Aktionär hier einstellen?

Danke und schönes Wochenende.

[Canadian2000]

Bin heute auch mal zu 3,67 rein!

Schönes Wochenende!

[xwin]

na da hat aber jemand schön Gewinne realisiert. In zwei Wochen ärgert er/sie sich bestimmt

[xwin]

Heute 15:15 Bericht auf n-tv über Nanotechnologie (allgemein, nicht CMBX spezifisch)

[xwin]

15:35 - sorry

[Brokerprofi]

Hier noch einmal der Link zum Deal CBMX mit US-Regierung (Militär)

http://tinyurl.com/23bdq

Die haben sicher CMBX von allen Seiten (skills, capabilities, financial strength) beleuchtet bevor dieser Auftrag vergeben wurde.

Das ist eine bessere Empfehlung zum Kauf der Aktie als es je ein Analyst mit strong buy oder outperformer abgeben könnte!!!

gruß
brokerprofi

[xwin]

Combimatrix Empfehlung in der Aktionär.

Hier der Link mit Real Audio Vorstellung des Unternehmens

Hört sich gut!!!

http://www.deraktionaer.de/Interview.phtml?current=1082481

[Quadian]

http://nano.ivcon.org/modules.php?name=News&file=article&sid…

[xwin]

kein so guter Tag heute. Irgendwie sind alle meine US Technologietitel dick im minus.

Was ist bei CMBX passiert? Gab doch ansich nur gute Nachrichten. Jedenfalls nicht enttäuschendes ausserhalb der Erwartungen???

[Brokerprofi]

halte ich erst mal für noch nicht so schlimm (Umsätze lagen gestern unter dem Durchschnitt, der Markt performte insgesamt in der letzten Stunde schlecht, Biotech regiert volatiler als andere Bereiche)
Erst mal sehen, was heute passiert.
Hilfreich wären positive Überraschungen im Tech-Bereich im Rahmend er Quartalsberichte.

Gruß
brokerprofi

[xwin]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Brokerprofi]

ich bin jedenfalls noch drin, könnte sich lohnen

http://biz.yahoo.com/bw/040720/205242_1.html

auch wenn dies `collaboration` noch lange keine Erlöse bringen wird.

Jetzt noch gute Q2-Ergebnisse verbunden mit einem positiven Ausblick, dann könnte es wieder nach oben gehen.

gruß
brokerprofi

[xwin]

es gab nen verhältnismässig interessanten Bericht auf FOX mit dem CEO von CMBX. Der hat den DNA Chip zur Erkennung von Biogefahren vorgestellt. Mittelfristig will man das Ding in ein Rauchmelderartiges Gehäuse einbauen so dass jeder hysterische Amerikaner sich sowas in die Wohnung schrauben kann.

Das ist zumindest ein MASSENMARKT. Sollte Al-Quaida tatsächlich in der Lage sein einen Bio-Angriff zu starten (hoffentlich nicht!!!) oder gibt es zumindest diesbezüglich eine Hysterie in den USA (von mir aus) dann ist CMBX ne Goldgrube weil sie als einziger die Technik bislang so modifiziert bekommen haben.

hier der Link zum MPEG Beitrag.

http://www.combimatrix.com/news_fox071804.htm

[hooray1]

Tja, im Moment sieht`s eher so aus als ob die Aktie IMplodiert anstatt EXplodiert..
Macht - wie der ganze Tec-Sektor im Moment - nicht grade eben allzuviel Spass..

[xwin]

scheinbar macht die Vernetzung mit Acacia den Anlegern immer noch Bauchschmerzen.

CMBX hat aber einiges in der Pipeline an Produkten und der Kurs ist nun mal sehr volatil. Schnell kann es runter gehen und schnell wieder hoch. Ist ja quasi noch ein Start-Up. Wir müssen Geduld haben. Ich finde die Entwicklung auch nicht so schön aber keineswegs dramatisch.

[brezlbua]

...im aktuellen Aktionär wird Combimatrix im Rahmen der Titelgeschichte als 75-Prozent-Chance vorgestellt.

[xwin]

die sind auch mein persönlicher Favourit für das nächste Jahr. Die Technologie ist absolut klasse. Die Anwendungen und Möglichkeiten wachsen immer mehr und es ist m.A. nach nur eine Frage der Zeit bis die Verkaufszahlen stark anstiegen. Von Gentechnik Schnelltests bis Biowaffendetektor lässt sich mit den Chips alles machen. Bin aber auch einigermassen enttäuscht über die Performance der Aktie auch wenn sie ja nicht sooo schlimm ist.

[xwin]

Im Yahoo Board munkelt man was von einer Kooperation mit Intel die bald veröffentlicht wird. Weiss jemand mehr drüber? Kurs steigt stark in Frankfurt. Wäre ja wunderbar wenn da etwas dran wäre.

[Quadian]

CombiMatrix and Intel Corporation Enter into Agreement
Wednesday September 8, 8:00 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Sept. 8, 2004--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group and Intel Corporation have entered into an agreement to work together on the feasibility of various projects utilizing CombiMatrix`s core technology. The terms and conditions of the agreement are confidential.

[Quadian]

http://www.nanoinvestornews.com/modules.php?name=News&file=a…


Frost & Sullivan: How different is CombiMatrix from other players in this market?

Dr Amit Kumar:
The key differentiator of our product
over most of the other products in the market
is that we provide complete flexibility to the customer.
Our focus is on customized microarrays. In addition,
CombiMatrix will be offering a desktop sized synthesizer,
which will allow researchers to design and build
customized arrays in their own facility.
A researcher will simply place blank CombiMatrix arrays
into their CombiMatrix synthesizer and it will
automatically produce custom arrays,
based on sequences chosen, in 24 hours.

Our technology enables customers to use these arrays
to validate certain probes before they
get involved in high volume studies.
Our technology is very complimentary
to some of the other products on the market
and we don’t see ourselves competing against companies
that are developing and selling whole human genome microarrays.


Frost & Sullivan: Can you give an overview of your Toppan deal?

Dr Amit Kumar:
Toppan is a large Japanese company with nearly $12 billion in annual sales.
One of their businesses is in microelectronics and
they have an interest in moving into the biotech space.
Toppan has a lot of expertise in designing and
building semiconductor devices and became interested in
CombiMatrix’s ability to apply semiconductors to the biotech sector.
Toppan is going to help us design our next generation semiconductor device,
which will detect molecules on our chips electrochemically.

Today we build molecules on our arrays electrochemically.
Our plan with Toppan is to design a next generation chip that
will not only build the molecules on our chip electrochemically,
but also detect and read the chip electrochemically. In the end,
Toppan’s interest is to be the manufacturer of these microarrays
and our interest is to distribute them by ourselves or through other partners.


Frost & Sullivan: Where do you see your company in the competitive landscape?

Dr Amit Kumar:
CombiMatrix’s technology is being applied in many different areas.
In some areas we are commercializing our products, like DNA microarrays,
where we think we have the best technology for customized microarrays in the world.

In the area of defense, certainly there are some other companies
that have been working in this area for a longer period of time and
have focused more resources on it. However, once we complete
the developments of our products we believe our expertise and
technological advances will be evident.

In the siRNA drug discovery area, we along with everyone else
are pretty much in the same stage. The whole industry and
academic community are learning how siRNA’s operate in the body.

In the nanotechnology area, we have been working for quite some time
and have established a number of key strategic partnerships,
which we think will enable us to get products on the market
some time in the near future.


Frost & Sullivan: If you had one thing for your clients to know
about CombiMatrix, what would it be?

Dr Amit Kumar:
Well I think clients should know that we are unique relative to
other biotech companies because we are a development stage company,
which has just begun to commercialize its products.
Even though we are doing R&D, we have not burnt a huge amount of cash
because we have been able to execute a strategy that has allowed us
to access capabilities and cash from a number of strategic partners
such a

[mystreet]

Hallo, nachdem auch Intel mit denen zusammen arbeiten will - also eine total andere Branche, wo die Produkte auch non Nutzen sein können - müßten die momentanen Kurse um 2,30 eigentlich eine Super-Gelegenheit sein, oder ??

Weitere positive News:
CombiMatrix and SAIC to Jointly Develop Biothreat Identification Microarrays

BW5180 OCT 14,2004 5:31 PACIFIC 08:31 EASTERN

( BW)(CA-ACACIA/COMBIMATRIX)(CBMX)(ACTG) CombiMatrix and SAIC toJointly Develop Biothreat Identification Microarrays

Business Editors/Biotech Writers
BIOWIRE2K

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Oct. 14, 2004--AcaciaResearch Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today thatits CombiMatrix group and Science Applications InternationalCorporation (SAIC), the nation´s largest employee-owned research andengineering company, will work together to develop microarrays for theidentification of multiple biothreat organisms. Both companies haveDepartment of Defense (DoD) contracts from the Defense ThreatReduction Agency that support the development and delivery ofcomplementary products. Leveraging their respective DoD funding canhelp expedite the development and testing of new identification anddiagnostic assays and products against conventional biothreat agentsand emerging and genetically engineered pathogens.
SAIC has developed a genome assay and data mining tools thatidentify genomic sequences that are unique to specific microbialbiothreat agents. Dr. R. Paul Schaudies, SAIC Vice President ofChemical and Biological Defense, explained, "By combining thebioinformatics of our proprietary Fast Identification of UniqueGenomic Regions (FIGUR) software with a highly-multiplexed microarraywe can hopefully make false positive readings a thing of the past.Protocols and procedures, along with microarrays, will be transferredto government laboratories for independent validation."
CombiMatrix has developed a microarray platform, based uponcomplementary metal oxide semiconductor (CMOS) technology. Throughproprietary instrumentation and probe design software, CombiMatrix canproduce single or multiple microarrays with unique DNA sequences oneach of its 12,000 features. This gives the customer a rapid andversatile approach to defining and changing microarray array content.Under the DoD contract, CombiMatrix is developing electrochemicaldetection as an alternative to the current use of large and expensiveoptical readers and dyes used in fluorescence detection.
"We are pleased to be working with SAIC towards a common goal thatwill benefit the DoD and our nation," said Dr. David Danley, Directorof Homeland Security and Defense Programs for CombiMatrix. "Thiseffort allows us to leverage our DoD resources using proven assays andtechnologies. When we have completed development of electrochemicaldetection, we will then be able to move genomic assays out of the laband into the field."

Was meint Ihr?

[mystreet]

Top-News für eine Top-Aktie
==> Kurspotential: kurzfristig 4 € und Ende 2005 5-6 €
Wetten das!

[Quadian]

This post is for new shareholders and potential shareholders.

Combimatrix has four key business areas. They are drug development, custom microarrays, nanotechnology, and homeland security (chem/bio detector). The company website is a great place to start also to get a feel for the company. The company revolves around its core technology that uses semiconductor-based in situ electochemical synthesis platform.


There have been much product development in all four areas for many years. Recently, Custom array chips have been commercialized. The current quarter will be the first full quarter of array sales. The array sales will be a significant product revenue producer in 2005.

Below I listed my conservative view on possible sales in 2005:

1. Customarray sales could range from 15-30 million in revenues for 2005.

2. An array synthesizer will be launched in 2005 with the collaboration of a Japanese company called Furuno. Milestones payments of 2 million by Furuno and royalty revenues of 1 to 5 million dollars from product sales.

3. The Chem/bio detector will be closer to being finished and roughly 10 million will be payed as deffered revenue to combimatrix from US Dept of Defense. Potential distributor/manufacturing may be announced as well. Perhaps product launch in 2006 and revenues?

4. Matrixarray may be launched by partner Roche Diagnostics in early part of 2005. Expect to see royalty payments in later part of 2005. Revenue of 1 - 10 million? Deffinately will increase in 2006.

5. Nano workstation sales with NDC. Revenue of 1 million?

6. Intel is working with CBMX on a confidential project. Hard to figure out how much will come from it. It could be similar to a Roche relationship of milestone payments and product revenues. Revenues of 1 to 15 million in 2005?

7. Toppan involved with CBMX on the development of electrochemical detection using microarrays. Perhaps an extension of the relationship and milestome payments. 1-4 million in revenue.

The drug area for CBMX is still a few years down the road from any product revenue. Perhaps a drug company will partner with CBMX to bring the HIV siRNA cocktail through clinical trials. Or maybe CBMX will license the drug to a larger drug company.

So you can see that CBMX is transitioning into a company that is selling many products or will begin to. Revenues could be easily 25 - 50 million next year if not more. I would expect 2006 to really be even bigger based on product penetration. It takes time to ramp sells.

Hope this helps get a bigger picture of the company in terms of potential revenues next year.

Good Luck!

[Carloaktien]

Hallo alle zusammen!
Ich beobachte die Combimatrix Aktie schon seit geraummer Zeit und denke ein Einstieg wäre jetzt günstig.
Sie kratzt am unteren Limit und im laufenden Jahre müssten erste Produkte gewinn bringend verkauft werden.
Bin kein großer Experte, wollte deshalb andere User nach der Meinung fragen.
Lohnt sich jetzt ein Einstieg. 2,35 € ?
3 € Sind denke ich kurzfristig locker drin. Bei guten News sogar Verdopplung denke ich.
Danke im Vorraus,
Carlo

[glckschweinchen]

carloaktien
hallo zusammen! glaube auch das der zeitpunkt(kurz oder langfristig)in combimatrix einzusteigen günstig ist. bin zwar auf dem gebiet auch kein experte schätze aber das 10-20% in den nächsten tagen drinn sind.bin heute im amiland um3,1 usd rein gegangen.schauma mal. würde mich über meinungen freuen tschau!

[neatneatneat]

[Carloaktien]

Prognosen und Kursverlauf sehen verdammt gut aus!
Freu mich schon auf stabilen Zuwachs!
Carlo

[Mommax]

Guten Abend,
es ist außerordentlich still um diese Aktie geworden. Auch die Kursentwicklung ist enttäuschend! Weiß denn jemand wann Zahlen veröffentlicht werden? Falls ja, wäre ich über diese Information sehr dankbar da ich immernoch investiert bin.
Danke im Voraus
Mommax

[Mommax]

Hi Zusammen,
habe selbst die Antwort unter www.Yahoo.de gefunden, vielleicht ist noch jemand daran interessiert:
Acacia Research to Release Second Quarter Financial Results and Host Conference Call

Acacia Research Corporation (Nasdaq:ACTG) (Nasdaq:CBMX) announced today it will release its second quarter financial results on Tuesday, July 26, 2005. Results will be released at the close of trading on the NASDAQ national market.

A conference call is scheduled for the same day.

The Acacia Technologies Group presentation and Q&A will start at 1:15 p.m. Pacific Time (4:15 p.m. Eastern).

The CombiMatrix Group presentation and Q&A session will start at 1:45 p.m. Pacific Time (4:45 p.m. Eastern).

To listen to the presentation by phone, dial [phone] for domestic callers and [phone] for international callers, both of whom will need to provide the operator with the confirmation code 1494274. A replay of the audio presentation will be available for 30 days at [phone] for domestic callers and [phone] for international callers, both of whom will need to enter the code 1494274 when prompted.

The call is being webcast by CCBN and can be accessed at Acacia`s website at www.acaciaresearch.com.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 30 patent portfolios, which include 128 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, Internet access redirection, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix`s technology has a wide range of applications including DNA synthesis/diagnostics, drug discovery, and immunochemical detection. CombiMatrix`s Express Track(sm) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Quelle: BUSINESS WIRE NEWS EXPRESS

19.07.2005 13:00:00 (BUSINESS WIRE NEWS EXPRESS)
Acacia Research to Release Second Quarter Financial Results and Host Conference Call

[Mommax]

Weiß jemand WO die Quartalszahlen die heute erscheinen sollten nachzulesen sind. Habe weder hier noch in Yahoo etwas gefunden.
Gruß Mommax

[Mommax]

Hi zusammen!
Mit dem Risiko als Alleinunterhalter abgestempelt zu werden stelle ich den Quartalsbericht von 26.07.05 hier rein. Wäre für eine Übersetzung sehr dankbar (falls jemand ein Übersetzungsprogramm hat) denn die Länge des Berichts ist doch beachtlich und dadurch schwer zu lesen. Quelle ist www.Onvista.de.
Gruß Mommax


WKN: 164630 ISIN: US0038812089 Branche: Dienstleistungen Land: USA

26.07.2005 22:00:00 (BUSINESS WIRE NEWS EXPRESS) versenden drucken > vor
15 Datensätze gefunden.
Acacia Research Reports Second Quarter Financial Results

Acacia Research Corporation (Nasdaq:ACTG) (Nasdaq:CBMX) today reported results for the three months ended June 30, 2005. Acacia Research Corporation comprises two operating groups, the Acacia Technologies group and the CombiMatrix group.

"Acacia Technologies group revenues for the second quarter of 2005 were $2,682,000, an increase of 44% from the previous quarter and over 300% from the year ago period. We generated revenues from 6 patent licensing programs, including revenues from 3 new programs, with initial licenses to Nokia for our multi-dimensional bar code technology, National Instruments for our computer simulation technology and Funai for our high capacity compact disk technology," commented Paul Ryan, Chairman & CEO of Acacia.

"We added Sony as a licensee for our interactive television technology, Patriot Media for our Digital Media Transmission (DMT(R)) technology, and Foot Locker, Petco, Too Inc., Tuesday Morning and Sterling Jewelers for our credit card fraud protection technology. Acacia is also pursuing 12 additional licensing programs, including our recently acquired laptop connectivity technology. We plan to continue acquiring new patent portfolios as we move toward our goal of becoming the leader in technology licensing," concluded Mr. Ryan.

"The CombiMatrix group`s revenues for the second quarter of 2005 were $1,857,000. This represents a gain of 74% over revenues from the first quarter of 2005, and gain of 147% over revenues of the second quarter of 2004. Product and equipment revenues related to CustomArray(TM) were $565,000, which represents an increase of 103% relative to such revenues earned in the first quarter of 2005 and over 1200% greater than such revenues for the second quarter of 2004," commented Dr. Amit Kumar, President and CEO of CombiMatrix Corporation.

"Last quarter we achieved our first one million dollar quarter, and during this quarter we nearly achieved our first two million dollar quarter. The CombiMatrix group continues to execute on its plan as our products become accepted in our industry. In addition to the aforementioned sales growth, we made advances in all facets of our business, and began execution of our diagnostics strategy by establishing CombiMatrix Molecular Diagnostics," concluded Dr. Kumar.

Acacia Research Corporation Consolidated

Financial Results

Consolidated revenues for the second quarter of 2005 were $4,539,000 versus $1,416,000 in the comparable 2004 period. Second quarter 2005 revenues recognized by the CombiMatrix group were $1,857,000, comprised of $1,281,000 in government contract revenues and $576,000 in CustomArray(TM) product, equipment and service revenues.

Second quarter 2005 revenues recognized by the Acacia Technologies group were $2,682,000, comprised of $832,000 in recurring license fee revenues and $1,850,000 in paid-up license fee revenues. Recurring license fee revenues are recognized from licensees that make recurring quarterly or annual license fee payments under their respective license agreements. Paid-up license fee revenues are recognized from licensees that make paid-up license fee payments for past infringement and future use of our patented technologies, in accordance with their respective license agreements. Certain of our paid-up license agreements provide for potential additional payments to the Acacia Technologies group based on future activities. All of the paid-up license fee revenues recognized in the second quarter of 2005 relate to patents acquired in the January 2005 acquisition of Global Patent Holdings, LLC (the "GPH Acquisition"). Second quarter 2005 license fee revenues included fees from the licensing of our Digital Media Transmission (DMT(R)) technology, credit card fraud protection technology, multi-dimensional bar code technology, computer simulation technology, high capacity compact disk technology and interactive television technology.

The second quarter 2005 consolidated net loss was $5,417,000 versus $4,669,000 in the comparable 2004 period. The second quarter 2005 results include net non-cash charges totaling $1,891,000, comprised primarily of patent amortization charges of $1,610,000 and asset depreciation charges of $266,000. Patent amortization, non-cash stock compensation and asset depreciation charges totaled $865,000 in the comparable 2004 period. The increase in patent amortization charges reflects the amortization of patent related intangibles acquired in connection with the GPH Acquisition. Patent amortization charges will continue to be significant in future periods as the Acacia Technologies group continues to amortize the acquired patent related costs over a weighted average economic useful life of approximately 6 years. The second quarter 2004 results included a non-cash credit of $391,000 related to changes in the fair value of AR-CombiMatrix common stock issuable in connection with certain anti-dilution provisions of the September 2002 settlement agreement with Nanogen, Inc. The anti-dilution provisions expire in September 2005.

Second quarter 2005 government contract costs totaled $1,209,000 versus $653,000 in the comparable 2004 period. The change was due to increased costs recognized in connection with the CombiMatrix group`s commitments under its biological threat detection cost plus fixed fee contract with the Department of Defense, which was originally awarded in March 2004. As of June 30, 2005, the biological threat detection contract is approximately 68% complete. Second quarter 2005 internal research and development expenses were $1,415,000 versus $1,409,000 in the comparable 2004 period. During the second quarter of 2005 and 2004, the CombiMatrix group continued internal research and development efforts to improve and expand the CombiMatrix group`s technology and product offerings. Government contract costs and research and development expense were incurred solely by the CombiMatrix group.

Marketing, general and administrative expenses for the second quarter of 2005 increased to $4,261,000 from $3,388,000 in the comparable 2004 period, due primarily to the addition of licensing and business development personnel for the Acacia Technologies group, an increase in the Acacia Technologies group`s consulting expenses related to a consulting agreement executed with the former CEO of Global Patent Holdings, LLC and an increase in marketing and sales expenses related to commercial sales of the CombiMatrix group`s CustomArray(TM) products and services.

Second quarter 2005 patent related legal expenses, comprised solely of costs incurred by the Acacia Technologies group, were $536,000 versus $576,000 in the comparable 2004 period. Second quarter 2005 patent related legal expenses included $278,000 in patent related prosecution and enforcement costs incurred by certain of the companies acquired in the GPH Acquisition transaction. Excluding the impact of the GPH Acquisition, patent related legal expenses decreased to $258,000 in the second quarter of 2005 due to a decrease in costs incurred in connection with the Acacia Technologies group`s ongoing DMT patent commercialization and enforcement programs, including decreased legal costs related to new patent claims and a decrease in patent enforcement costs related to ongoing DMT patent related litigation. DMT related legal fees paid to outside attorneys are incurred based on actual time and out-of-pocket expenses incurred by external counsel and fluctuate from period to period based on patent enforcement and prosecution activity in each period. DMT related legal expenses will fluctuate in future periods based on actual outside patent counsel fees incurred in connection with the Acacia Technologies group`s ongoing DMT patent commercialization and enforcement programs.

In the second quarter of 2005, the Acacia Technologies group recognized contingent legal fee expenses totaling $592,000 and inventor royalty expenses totaling $528,000, in connection with the recognition of related paid-up license fee revenues.

Financial Condition

Total consolidated assets were $116,757,000 as of June 30, 2005 compared to $88,327,000 as of December 31, 2004. Cash and cash equivalents and short-term investments on a consolidated basis totaled $55,331,000 as of June 30, 2005 compared to $52,358,000 as of December 31, 2004.

In June 2005, Acacia Research Corporation obtained commitments to purchase approximately $3.2 million of its Acacia Research-CombiMatrix common stock in a registered direct offering, which closed on July 5, 2005. Under the terms of the transaction, 1,400,444 shares of Acacia Research-CombiMatrix common stock were sold at $2.25 per share to a select group of institutional investors. The net proceeds, totaling approximately $3.1 million, which are net of offering costs, were allocated to the CombiMatrix group. All of the shares of Acacia Research-CombiMatrix common stock were offered by Acacia Research Corporation pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.

Acacia Technologies Group

(A Division of Acacia Research Corporation)

Financial Results

License fee revenues for the second quarter of 2005 were $2,682,000 versus $666,000 in the comparable 2004 period. Second quarter 2005 revenues recognized by the Acacia Technologies group included $832,000 in recurring license fee revenues and $1,850,000 in paid-up license fee revenues. Recurring license fee revenues are recognized from licensees that make recurring quarterly or annual license fee payments under their respective license agreements. Paid-up license fee revenues are recognized from licensees that make paid-up license fee payments for past infringement and future use of our patented technologies, in accordance with their respective license agreements. Certain of our paid-up license agreements provide for potential additional payments based on future activities. All of the paid-up license fee revenues recognized in the second quarter of 2005 relate to patents acquired in the January 2005 GPH Acquisition. Second quarter license fee revenues included fees from the licensing of our Digital Media Transmission (DMT(R)) technology, credit card fraud protection technology, multi-dimensional bar code technology, computer simulation technology, high capacity compact disk technology and interactive television technology.

The second quarter 2005 division net loss was $1,760,000 versus $1,153,000 in the comparable 2004 period. Included in the second quarter 2005 divisional results are non-cash patent amortization charges totaling $1,336,000 versus $125,000 in the comparable 2004 period. Patent amortization charges increased in the second quarter of 2005 due to the amortization of patent related intangibles acquired in connection with the GPH Acquisition. Patent amortization charges will continue to be significant in future periods as we continue to amortize the acquired patent related costs over a weighted average economic useful life of approximately 6 years.

Second quarter 2005 marketing, general and administrative expenses increased to $1,759,000 from $1,160,000 in the comparable 2004 period, due primarily to the addition of licensing and business development personnel for the Acacia Technologies group and an increase in consulting expenses related to a consulting agreement executed with the former CEO of Global Patent Holdings.

Second quarter 2005 patent related legal expenses were $536,000 versus $576,000 in the comparable 2004 period. Second quarter 2005 patent related legal expenses included $278,000 in patent related prosecution and enforcement costs incurred by certain of the companies acquired in the GPH Acquisition transaction. Excluding the impact of the GPH Acquisition, patent related legal expenses decreased to $258,000 in the second quarter of 2005 due to a decrease in costs incurred in connection with the Acacia Technologies group`s ongoing DMT patent commercialization and enforcement programs, including decreased legal costs related to new patent claims and a decrease in patent enforcement costs related to ongoing DMT patent related litigation. DMT related legal fees paid to outside attorneys are incurred based on actual time and out-of-pocket expenses incurred by external counsel and fluctuate from period to period based on patent enforcement and prosecution activity in each period. DMT related legal expenses will fluctuate in future periods based on actual outside patent counsel fees incurred in connection with the Acacia Technologies group`s ongoing DMT patent commercialization and enforcement programs.

In the second quarter of 2005, the Acacia Technologies group recognized contingent legal fee expenses totaling $592,000 and inventor royalty expenses totaling $528,000, in connection with the recognition of related paid-up license fee revenues.

It is anticipated that the majority of litigation expenses associated with the recently acquired patent portfolios will be incurred on a contingency basis where patent attorney fees are paid out of license fee revenues collected based on a contractual percentage. In connection with the GPH Acquisition, we expect that other legal expenses associated with the maintenance, licensing and enforcement of our patented technologies, will increase in future periods as we continue to roll out our licensing programs for our recently acquired patented technologies.

Financial Condition

Total assets for the Acacia Technologies group were $67,658,000 as of June 30, 2005 compared to $33,058,000 as of December 31, 2004. Cash and cash equivalents and short-term investments totaled $39,158,000 as of June 30, 2005 compared to $28,646,000 as of December 31, 2004.

CombiMatrix Group

(A Division of Acacia Research Corporation)

Financial Results

Revenues for the second quarter of 2005 were $1,857,000 versus $750,000 in the comparable 2004 period. Second quarter 2005 revenues were comprised of $1,281,000 in government contract revenues and $576,000 in CustomArray(TM) product, equipment and service revenues.

Government contract revenues relate to the CombiMatrix group`s development of biological threat detection technology under its $5.9 million Department of Defense cost plus fixed fee contract, originally awarded in March 2004.

The second quarter 2005 division net loss was $3,657,000 versus $3,516,000 in the comparable 2004 period. The second quarter 2005 results include non-cash patent amortization, asset depreciation and stock compensation charges totaling $541,000 as compared to $727,000 in the comparable 2004 period. The second quarter 2004 results also included a non-cash credit totaling $391,000 related to changes in the fair value of AR-CombiMatrix common stock issuable in connection with certain anti-dilution provisions of the September 2002 settlement agreement with Nanogen, Inc. The anti-dilution provisions expire in September 2005.

Second quarter 2005 government contract costs totaled $1,209,000 versus $653,000 in the comparable 2004 period. The change was due to increased costs recognized in connection with the CombiMatrix group`s commitments under its biological threat detection cost plus fixed fee contract with the Department of Defense, which was originally awarded in March 2004. As of June 30, 2005, the biological threat detection contract is approximately 68% complete. Second quarter 2005 internal research and development expenses were $1,415,000 versus $1,409,000 in the comparable 2004 period. During the second quarter of 2005 and 2004, the CombiMatrix group continued internal research and development efforts to improve and expand the CombiMatrix group`s technology and product offerings.

Second quarter 2005 marketing, general and administrative expenses increased to $2,502,000 versus $2,228,000 in the comparable 2004 period, due primarily to an increase in marketing and sales expenses related to the CombiMatrix group`s CustomArray(TM) products and services.

Financial Condition

Total assets for the CombiMatrix group were $49,186,000 as of June 30, 2005 compared to $55,388,000 as of December 31, 2004. Cash and cash equivalents and short-term investments totaled $16,173,000 as of June 30, 2005 compared to $23,712,000 as of December 31, 2004.

In June 2005, Acacia Research Corporation obtained commitments to purchase approximately $3.2 million of its Acacia Research-CombiMatrix common stock in a registered direct offering, which closed on July 5, 2005. Under the terms of the transaction, 1,400,444 shares of Acacia Research-CombiMatrix common stock were sold at $2.25 per share to a select group of institutional investors. The net proceeds, totaling approximately $3.1 million, which are net of offering costs, were allocated to the CombiMatrix group. All of the shares of Acacia Research-CombiMatrix common stock were offered by Acacia Research Corporation pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.

Business Highlights and Recent Developments

Business highlights of the second quarter and recent developments include:

Acacia Technologies group:

-- As of July 2005, the Acacia Technologies group is pursuing 18 licensing and enforcement programs which include its audio/video enhancement and synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, data encryption and product activation, digital media transmission, digital video production, dynamic manufacturing modeling, image resolution enhancement, interactive television, interstitial Internet advertising, high capacity compact disks, laptop connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, spreadsheet automation, and resource scheduling technologies. As of July 2005, the Acacia Technologies group has executed license agreements and recognized revenues from 7 of its ongoing licensing and enforcement programs.

-- In April 2005, Financial Systems Innovation LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, entered into a non-exclusive license and settled patent infringement litigation covering the Acacia Technologies group`s credit card fraud protection technology with Petco Animal Supplies, Inc. The patented technology generally relates to a computerized system for protecting retailers and consumers engaged in credit card, check card and debit transactions.

-- In April 2005, VData, LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, entered into a license with Nokia Corporation covering a portfolio of patents that apply to certain multi-dimensional bar codes. The multi-dimensional bar code technology generally relates to encoding and reading a data matrix consisting of an array of data cells with a border. The data matrix can contain a variety, amount and depth of information that would not fit on to an ordinary bar code. This patented technology can have many applications in the manufacturing, distribution, operations, accounting and security industries such as tracking the movement of products, collection of data, improved production capabilities and anti-counterfeiting.

-- In April 2005, Microprocessor Enhancement Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, filed a patent infringement lawsuit in the District Court for the Central District of California against Intel Corporation and Texas Instruments Corporation. The lawsuit alleges infringement of Microprocessor Enhancement Corporation`s microprocessor enhancement technology patents by Intel`s Itanium(R) line of microprocessors, and certain series of digital signal processors sold by Texas Instruments. This patented technology generally relates to an architecture employed in advanced pipeline microprocessors. This architecture allows for conditional execution of microprocessor instructions, and a later determination of whether the instructions executed should be written back to memory. By conditionally executing instructions in this architecture, significant improvements in microprocessor speed can be achieved. Certain pipelined processor manufacturers are adopting this method of processing to improve processor speed.

-- In April 2005, Acacia Patent Acquisition Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, acquired a patent relating to a commonly used technology to connect laptop computers to peripheral devices via docking stations. The patented technology is used to connect a laptop or other portable computer to multiple external devices such as a keyboard, monitor, printer or mouse, through a single connector from the laptop to the docking station.

-- In April 2005, Acacia Media Technologies Corporation added Time Warner Cable, Cablevision Systems Corporation, Insight Communications Company, Cebridge Connections and Bresnan Communications to its DMT(R) patent infringement litigation. The lawsuit against Time Warner, Insight and Bresnan Communications was filed in the U.S. District Court for the Southern District of New York. The lawsuit against Cablevision Systems Corporation was filed in the Eastern District of New York, and the lawsuit against Cebridge Connections was filed in the Northern District of California. In accordance with the Transfer Order issued February 24, 2005, by the Judicial Panel on Multidistrict Litigation, all of the cases were transferred to the Northern District of California for consolidation with the existing DMT(R) litigation.

-- In May 2005, Computer Cache Coherency Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, added Intel Corporation and Advanced Micro Devices, Inc. to the patent infringement litigation for its Computer Memory Cache Coherency technology, which is pending in the District Court for the Northern District of California. Industry reports tracking 2003 sales of core logic chipsets by all manufacturers indicate total annual sales of approximately $4 billion, with Intel holding the largest market share. In December 2004, the Company filed a patent infringement lawsuit against Via Technologies, Inc., another core logic chipset market leader. The cases will likely be consolidated for pretrial purposes.

-- In May 2005, Financial Systems Innovation LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, entered into a non-exclusive license covering its credit card fraud protection technology with Tuesday Morning Corporation.

-- In May 2005, KY Data Systems, LLC, a wholly owned subsidiary that is part of the Acacia Technologies Group, entered into a non-exclusive license with Sony Corporation covering a portfolio of patents that apply to interactive television. The patents cover receivers such as set-top boxes and certain televisions used in digital satellite and digital cable systems that permit television viewers to access interactive television features supplied by their satellite and cable providers as part of their digital programming packages.

-- In May 2005, TechSearch, LLC, a wholly owned subsidiary that is part of the Acacia Technologies Group, entered into a non-exclusive license with Funai Electric Co., Ltd. covering a patent that applies to a system for recording and playing high capacity compact disks. The patent, currently being reexamined by the United States Patent and Trademark Office, covers certain systems for recording and playing compact disks containing compressed audio data utilizing certain data-compression methods.

-- In June 2005, the Acacia Technologies group entered into a license agreement for its Digital Media Transmission (DMT(R)) technology with Patriot Media, which provides cable TV services throughout central and northern New Jersey. The Acacia Technologies group`s DMT(R) technology involves the transmission and receipt of digital audio and/or audio video content via a variety of means including the internet, cable, satellite and local area networks. Elements of the DMT(R) transmission process include a source material library, identification encoding process, format conversion, sequence encoding, compressed data storage and transmission. Elements of the DMT(R) receiving process include a transceiver, format conversion, storage, decompression and playback.

-- In June 2005, Tech Search LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, entered into a non-exclusive license with National Instruments covering a portfolio of patents that apply to computer simulation systems. The patents cover aspects of computer simulation systems which can iteratively simulate a complex system represented by a network of interconnected function blocks and enable the user to graphically program their simulations.

-- In June 2005, Financial Systems Innovation LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, entered into non-exclusive licenses covering its credit card fraud protection technology with Sterling Jewelers, Too Inc. (operator of Limited Too and Justice stores) and Foot Locker, Inc.

-- In July 2005, Financial Systems Innovation LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, entered into a non-exclusive license covering its credit card fraud protection technology with LensCrafters, Inc., Sunglass Hut Trading Corporation, Pearle Vision, Inc., Cole Vision Corporation, Watch World International, Inc. and Things Remembered, Inc.

-- In July 2005, Acacia Patent Acquisition Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, acquired several patents covering electromagnetic compatibility shielding ("ECS") technology commonly incorporated into hearing aids. The patented technology shields hearing aids from electromagnetic interference produced by portable electronic devices such as cell phones, cordless phones, wireless headphones and headsets, and WIFI and Bluetooth enabled devices. The ECS technology can be incorporated into many styles of hearing aids.

-- In July 2005, Intel Corporation filed a Complaint in the District Court for the Northern District of Illinois against Information Technology LLC, a wholly owned subsidiary that is part of the Acacia Technologies group, seeking a Declaratory Judgment of non-infringement of a patent relating to Information Technology`s Dynamic Manufacturing Modeling technology. The Dynamic Manufacturing Modeling technology generally relates to a modeling and control process used to decrease costs and increase production for factory operations. Such simulation modeling can include a variety of parameters such as products, fabrication sequences, collections of job sets, scheduling rules and machine reliability standards. This technology can be used for exacting manufacturing processes such as semiconductor fabrication.

-- In July 2005, Spreadsheet Automation Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, commenced a patent infringement lawsuit in the District Court for the Eastern District of Texas against Microsoft Corporation. The suit alleges the unauthorized use by certain Microsoft products, including without limitation certain versions of Microsoft Access and Microsoft Excel, of our Spreadsheet Automation technology. The Spreadsheet Automation technology generally relates to automating the production of worksheet files for use by electronic spreadsheet programs. Specifically, the patented technology permits the efficient retrieval of data from external databases by allowing the user to select specific data from a database and import the specified data into a spreadsheet program through uniquely streamlined spreadsheet commands. The adaptive quality of the technology permits, among other things, the user to retrieve updated information from an external database without creating formatting issues in the user`s spreadsheet program.

CombiMatrix group:

-- In May 2005, the CombiMatrix group entered into a non-exclusive distribution agreement with Inter Medical to distribute the CombiMatrix group`s CustomArray(TM) products in Japan. Inter Medical will market, sell and service the CustomArray products in the Japanese marketplace.

-- In May 2005, CombiMatrix Corporation formed a wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. ("CMD"), to take advantage of CombiMatrix`s unique approach to array-based diagnostics. Matthew C. Watson was named Chief Executive Officer, and David A. Baunoch, Ph.D. was named President and Chief Operating Officer of CMD. Mr. Watson and Dr. Baunoch come to CMD from US LABS, which was recently acquired by Laboratory Corporation of America, where they were Vice President of Laboratory Operations and Vice President of Research and Development, respectively. Both executives bring to CMD more than 20 years of industry experience and a track record of building successful companies.

-- In June 2005, the CombiMatrix group entered into a co-development agreement with STMicroelectronics ("ST"), a global leader in the development and manufacturing of semiconductor products. The co-development will combine the CombiMatrix group`s proprietary electrochemical detection technology with ST`s In-Check(TM) Lab-on-Chip platform to investigate the feasibility of addressing the research and point-of-care diagnostics markets. Under the terms of the agreement, in addition to the sharing of technology and knowledge, ST will financially support the CombiMatrix group in this work.

-- In July 2005, the CombiMatrix group entered into a non-exclusive agreement with J.K. International Inc. to distribute the CombiMatrix group`s CustomArray(TM) products in Japan. J.K. International`s marketing and sales organizations will market, sell and service the CustomArray products in the Japanese marketplace.

-- In July 2005, the CombiMatrix group expanded the management team at CMD and appointed Dr. Mathew Moore as Director of Research and Development, Robert Embree as Director of Laboratory Operations and John Besser as Chief Financial Officer. The three executives bring to CMD more than 40 years of combined industry experience and a track record in building successful diagnostic companies.

A conference call is scheduled for today. The Acacia Technologies Group presentation and Q&A will start at 1:15 p.m. Pacific Time (4:15 p.m. Eastern). The CombiMatrix Group presentation and Q&A session will start at 1:45 p.m. Pacific Time (4:45 p.m. Eastern).

To listen to the presentation by phone, dial 800-406-5345 for domestic callers and 913-981-5571 for international callers, both of whom will need to provide the operator with the confirmation code 1494274. A replay of the audio presentation will be available for 30 days at 888-203-1112 for domestic callers and 719-457-0820 for international callers, both of whom will need to enter the code 1494274 when prompted.

The call is being webcast by CCBN and can be accessed at Acacia`s website at www.acaciaresearch.com.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires and licenses patented technologies. Acacia controls 31 patent portfolios, which include over 120 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, Internet access redirection, interstitial Internet advertising, laptop connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, and spreadsheet automation.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

ACACIA RESEARCH CORPORATION
SUMMARY FINANCIAL INFORMATION
(In thousands, except share and per share information)
(Unaudited)

CONSOLIDATED BALANCE SHEET INFORMATION

June 30, December 31,
2005 2004
-------- ------------

Total Assets $116,757 $ 88,327
======== ============
Total Liabilities $ 12,214 $ 11,913
======== ============
Minority Interests $ 482 $ 778
======== ============
Total Stockholders` Equity $104,061 $ 75,636
======== ============

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months For the Six Months
Ended Ended
----------------------- -----------------------
June 30, June 30, June 30, June 30,
2005 2004 2005 2004
----------- ----------- ----------- -----------
Revenues:
Research and
development contract $- $- $- $17,302
License fees 2,682 666 4,545 1,265
Government contract 1,281 701 2,012 918
Products and services 576 49 914 146
----------- ----------- ----------- -----------

Total revenues 4,539 1,416 7,471 19,631
----------- ----------- ----------- -----------

Operating expenses:
Cost of government
contract revenues 1,209 653 1,900 858
Cost of product sales 190 36 353 40
Research and
development expenses 1,415 1,409 2,555 2,792
Non-cash stock
compensation
amortization -
research and
development - 32 - 101
Marketing, general
and administrative
expenses 4,261 3,388 8,150 6,672
Legal expense -
patents 536 576 1,097 1,178
Contingent legal fees
and inventor
royalties expense -
patents 1,120 - 1,767 -
Non-cash stock
compensation
amortization -
marketing, general
and administrative 15 143 (111) 477
Amortization of
patents 1,610 399 2,800 798
Legal settlement
charges (credits) (16) (391) (195) 866
----------- ----------- ----------- -----------

Total operating
expenses 10,340 6,245 18,316 13,782
----------- ----------- ----------- -----------

Operating income
(loss) (5,801) (4,829) (10,845) 5,849
----------- ----------- ----------- -----------

Other income (expense):
Interest income 382 192 655 350
Other expense (62) - (101) -
----------- ----------- ----------- -----------

Total other income 320 192 554 350
----------- ----------- ----------- -----------

Income (loss) from
continuing operations
before income taxes
and minority interest (5,481) (4,637) (10,291) 6,199

Benefit for income
taxes 64 69 134 136
----------- ----------- ----------- -----------

Income (loss) from
continuing operations
before minority
interests (5,417) (4,568) (10,157) 6,335

Minority interests - 3 - 3
----------- ----------- ----------- -----------

Income (loss) from
continuing operations (5,417) (4,565) (10,157) 6,338
----------- ----------- ----------- -----------

Discontinued operations:

Estimated loss on
disposal of discontinued
operations - (104) (210) (104)
----------- ----------- ----------- -----------

Net income (loss) $(5,417) $(4,669) $(10,367) $6,234
=========== =========== =========== ===========

Earnings (loss) per
common share:
Attributable to the
Acacia Technologies
group:
Net loss $(1,760) $(1,153) $(3,634) $(2,142)
Basic and diluted loss
per share (0.06) (0.06) (0.14) (0.11)

Attributable to the
CombiMatrix group:
Basic
Net income (loss) $(3,657) $(3,516) $(6,733) $8,376
Basic earnings (loss)
per share (0.12) (0.12) (0.22) 0.29
Diluted
Net income (loss) $(3,657) $(3,516) $(6,733) $8,376
Diluted earnings
(loss) per share (0.12) (0.12) (0.22) 0.28

Weighted average shares:
Acacia Research -
Acacia Technologies stock:

Basic and diluted 27,271,416 19,787,466 25,922,412 19,769,901
=========== =========== =========== ===========
Acacia Research -
CombiMatrix stock:

Basic 31,200,984 30,459,576 31,200,742 28,867,101
=========== =========== =========== ===========
Diluted 31,200,984 30,459,576 31,200,742 30,385,512
=========== =========== =========== ===========


ACACIA TECHNOLOGIES GROUP
(A Division of Acacia Research Corporation)
SUMMARY FINANCIAL INFORMATION
(In thousands)
(Unaudited)

GROUP BALANCE SHEET INFORMATION

June 30, December 31,
2005 2004
--------- ------------

Total Assets $ 67,658 $ 33,058
========= ============
Total Liabilities $ 3,254 $ 3,472
========= ============
Minority Interests $ 482 $ 778
========= ============
Total Stockholders` Equity $ 63,922 $ 28,808
========= ============


GROUP STATEMENTS OF OPERATIONS

For the Three For the Six
Months Ended Months Ended
----------------- -----------------
June 30, June 30, June 30, June 30,
2005 2004 2005 2004
-------- -------- -------- --------

Revenues:
License fees $2,682 $666 $4,545 $1,265
-------- -------- -------- --------

Total revenues 2,682 666 4,545 1,265
-------- -------- -------- --------

Operating expenses:
Marketing, general and
administrative expenses 1,759 1,160 3,369 2,166
Legal expenses - patents 536 576 1,097 1,178
Contingent legal fees and inventor
royalties expense - patents 1,120 - 1,767 -
Amortization of patents 1,336 125 2,252 250
-------- -------- -------- --------

Total operating expenses 4,751 1,861 8,485 3,594
-------- -------- -------- --------

Operating loss (2,069) (1,195) (3,940) (2,329)
-------- -------- -------- --------
Other income:
Interest income 278 108 449 220
Other income 1 - 1 -
-------- -------- -------- --------

Total other income 279 108 450 220
-------- -------- -------- --------

Loss from continuing operations
before income taxes
and minority interests (1,790) (1,087) (3,490) (2,109)

Benefit for income taxes 30 35 66 68
-------- -------- -------- --------

Loss from continuing operations
before minority interests (1,760) (1,052) (3,424) (2,041)

Minority interests - 3 - 3
-------- -------- -------- --------

Loss from continuing operations (1,760) (1,049) (3,424) (2,038)

Discontinued operations:

Estimated loss on disposal of
discontinued operations - (104) (210) (104)
-------- -------- -------- --------

Division net loss $(1,760) $(1,153) $(3,634) $(2,142)
======== ======== ======== ========


COMBIMATRIX GROUP
(A Division of Acacia Research Corporation)
SUMMARY FINANCIAL INFORMATION
(In thousands)
(Unaudited)

GROUP BALANCE SHEET INFORMATION

June 30, December 31,
2005 2004
--------- ------------

Total Assets $ 49,186 $ 55,388
========= ============
Total Liabilities $ 9,047 $ 8,560
========= ============
Minority Interests $ - $ -
========= ============
Total Stockholders` Equity $ 40,139 $ 46,828
========= ============


GROUP STATEMENTS OF OPERATIONS

For the Three For the Six
Months Ended Months Ended
----------------- -----------------
June 30, June 30, June 30, June 30,
2005 2004 2005 2004
-------- -------- -------- --------

Revenues:
Research and development
contract $- $- $- $17,302
Government contract 1,281 701 2,012 918
Products and services 576 49 914 146
-------- -------- -------- --------

Total revenues 1,857 750 2,926 18,366
-------- -------- -------- --------

Operating expenses:
Cost of government contract
revenues 1,209 653 1,900 858
Cost of product sales 190 36 353 40
Research and development expenses 1,415 1,409 2,555 2,792
Non-cash stock compensation
amortization - research and
development - 32 - 101
Marketing, general and
administrative expenses 2,502 2,228 4,781 4,506
Non-cash stock compensation
amortization - marketing, general
and administrative 15 143 (111) 477
Amortization of patents 274 274 548 548
Legal settlement charges (credits) (16) (391) (195) 866
-------- -------- -------- --------

Total operating expenses 5,589 4,384 9,831 10,188
-------- -------- -------- --------

Operating income (loss) (3,732) (3,634) (6,905) 8,178
-------- -------- -------- --------

Other income (expense):
Interest income 104 84 206 130
Other expense (63) - (102) -
-------- -------- -------- --------

Total other income 41 84 104 130
-------- -------- -------- --------

Income (loss) from operations
before income taxes (3,691) (3,550) (6,801) 8,308

Benefit for income taxes 34 34 68 68
-------- -------- -------- --------

Division net income (loss) $(3,657) $(3,516) $(6,733) $8,376
======== ======== ======== ========


Quelle: BUSINESS WIRE NEWS EXPRESS

26.07.2005 22:00:00 (BUSINESS WIRE NEWS EXPRESS)
Acacia Research Reports Second Quarter Financial Results
08.03.2005 13:00:00 (BUSINESS WIRE NEWS EXPRESS)
Acacia Technologies Licenses Digital Video Production Patents to Leitch Technology
24.02.2005 22:00:00 (BUSINESS WIRE NEWS EXPRESS)
Acacia Research Reports Fourth Quarter and Year End Financial Results
22.02.2005 19:00:00 (BUSINESS WIRE NEWS EXPRESS)
CombiMatrix and Benitec Enter Cross-Licensing and Collaboration Agreement
22.02.2005 13:00:00 (BUSINESS WIRE NEWS EXPRESS)
Acacia Research to Release Fourth Quarter Financial Results and Host Conference Call
17.02.2005 15:00:00 (BUSINESS WIRE NEWS EXPRESS)
CombiMatrix Initiates Animal Studies on Therapeutic Compound to Treat Exposure to Terror Weapons
10.02.2005 13:00:00 (BUSINESS WIRE NEWS EXPRESS)
Acacia Technologies Group to Receive $19.6 Million from Acacia Research Registered Direct Offering
02.02.2005 13:00:00 (BUSINESS WIRE NEWS EXPRESS)
Acacia Technologies Licenses Interactive Television Patents to Thomson
01.02.2005 14:00:00 (BUSINESS WIRE NEWS EXPRESS)
CombiMatrix Set to Attend NanoBusiness Alliance Policy Tour in Washington D.C.
31.01.2005 13:01:00 (BUSINESS WIRE NEWS EXPRESS)
Acacia Technologies Completes Acquisition of Rights to 27 Patent Portfolios; Acquisition Expands Revenue Generating Opportunities


Suchbegriff: Zeitraum: heute1 Woche1 Monat3 Monategesamtes Archiv




Bücher Researchmaterialien Specials
Stillhaltergeschäfte
Technische Kumulationsanalyse
Marktberichte von HSBC
Kostenlose Geschäftsberichte
Auto-Special




Wie bewerten Sie diese Seite? sehr gut 1 2 3 4 5 6 schlecht



Partner:
Reise-Krankenvers. direkt abschließen
Kauftipps für HEBELZERTIFIKATE?
DAX-Börsenbrief abonnieren
Emerging-Markets-Trader
Top Schiffsbeteiligungen exklusiv!
ROHSTOFF-Börsenbrief testen
NEU: Fidelity MoneyBuilder Fonds!
Renditestarke & kostengünstige ETFs!
Hohe Gewinne mit neuronalem System!
DEVISEN-Börsenbrief abonnieren
Kostenloses Depot und Top-Konditionen!
BMW Sparkonto - 2,60% Top-Zins!



© 1998-2005 OnVista Group - Die OnVista Media GmbH übernimmt keine Haftung für die Richtigkeit der Angaben!
IS.eFinance Solutions implemented and powered by IS.Teledata AG
Informationen zur Zeitverzögerung der Kursdaten und Börsenbedingungen.
OnVista ist eine Marke der OnVista Media GmbH | Kurse und Schätzungen: Data Supplied by Thomson Financial
Besuchen Sie auch Onmeda, das neue Gesundheitsportal der OnVista Group.

AGB | Disclaimer/Nutzungsbedingungen | Impressum | Datenschutz

[glckschweinchen]

Mommax
Damit du mir hier nicht vereinsamst muss ich auch mal meinen senf dazu geben.Bin auch ein paar wochen in combimatrix drinnen,(was ich mir sparen hätte können)ca bei 2,55 USD eingestiegen.die zahlen müssten eigentlich gut gewesen sein den am 26.7stieg der kurs auf ca.2,6USD.
Worauf sie wieder auf 2,2abschmierte
Hast du zwischenzeitlich villeicht heraus gefunden wie man die zahlen einschätzen sollte.
Hi Mommax trotzdem schönes WE

[doktor7]

Hallo, ihr wackeren Einzelkämpfer

Tja, wie soll man die Zahlen schon einschätzen?

Es werden, grob gesagt, ca. doppelt so viel Verluste
gemacht, wie Umsätze generiert.

Wobei 2005 eher schlechter, als 2004, gelaufen ist.

Und insofern auch die Zukunfts-Fantasie gedämpft wurde.


gruß.....d7

[Aptamilla]

[posting]17.460.139 von doktor7 am 05.08.05 15:00:46[/posting]Nach näheren Hinsehen sind die Zahlen grottenschlecht.Auf diesem Niveau nicht kaufenswert.Hast es gut erkannt!

[Aptamilla]

[posting]17.460.139 von doktor7 am 05.08.05 15:00:46[/posting]Nur noch raus,raus und nochmals raus!!!

[puddy66]

Aptamilla,

rein, rein, und nochmals rein kann ich nur sagen!!
so billig bekommt ihr diese aktien nie wieder!
die Zukunft wird siegen!!!!!!

[notebook]

Bei dieser Aktie braucht man sich doch nur die Volumen anzusehen und schon weiss man, wann man kaufen und wann man verkaufen sollte.

[notebook]

Chart Börse Stuttgart.

Schaut euch mal an, wann in Deutschland die Anleger wie wild gekauft haben. - Da waren die Amis schon längst draussen.

[notebook]

Stand institutionelle Anleger per 24.08.05: 4%

[notebook]

Habe mal den Stand der institutionellen Anleger hier reingestellt. Mal schauen, wie sich der Anteil entwickelt. Die Aktie ist interessant. Ein Volumenanstieg und/oder Anstieg der institutionellen Anleger könnte ein Kaufsignal sein. (Meinung eines Nicht-Börsenfachmannes)

Grüsse
notebook

[notebook]

Stand institutionelle Anleger per 24.08.05: 4%

[notebook]

[notebook]

[notebook]

[notebook]

[POOL333]

[posting]17.671.165 von notebook am 24.08.05 16:22:54[/posting]könnte sich in den letzten tagen geändert haben.

[notebook]

Wieso?

[notebook]

[notebook]

OBV keine Anzeichen

[Aptamilla]

Oh Oh Oh,jetzt wird es bitter!Tendenz-1 Euro!

[notebook]

Wieso bitter? Ist doch gut! Je tiefer der Kurs fällt, desto grösser das Potential nach oben. Es gibt ja keinen Grund, weshalb die Aktie nicht wieder steigen sollte. Dass die Aktie allerdings weiter fällt ist charttechnisch nicht erstaunlich. Das war absehbar.

Wenn man den Langzeitchart betrachtet, so wird deutlich, dass hier Insiderspiele betrieben werden. Also spielen wir ein bisschen mit.

Grüsse
notebook

[notebook]

Langsam sind wir an einem historischen Tief. Wie tief soll denn das noch gehen?

Meinungen?

Diejenigen, welche sich schon länger mit der Aktie beschäftigen. Hat sich die Situation verschlechtert? Bitte ehrliche Antwort. Ansonsten auch vie BM.

Persönlich ist zwar das von mir erwartete Kaufsignal noch nicht eingetreten. Mache mir aufgrund des Allzeit-Tiefs aber trotzdem allmählich Gedanken über einen möglichen Einstieg. Wie seht ihr das?

Grüsse
notebook

[notebook]

Hab mir mal die Kurse in der Vergangenheit und die News angeschaut. Ist schon noch interessant. Die kommen jetzt mit allem, was hipp ist. SARS, HIV, Vogelgrippe, Nanotechnologie - je nach dem, was gerade anfällt. Und immer dann, wenn der Kurs tief ist.

Dann kommt hinzu, dass ja Roche auch ein Partner ist.

Das ist wieder mal so ne Firma, bei der man sich fühlt wie das Hauptgericht. Würde mich nicht erstaunen, wenn jetzt plötzlich irgend ne Meldung zur Vogelgrippe kommt. Die ist ja im Moment sehr aktuell.

Hat jemand ne Ahnung, wo man nachschauen kann, wann Roche Aktien von CMBX kauft? Das wäre die Insider-Info, die man hier bräuchte.

[notebook]

Ich geb euch mal ein Beispiel:

Oktober 04: Story beginnt: CBMX kommt mit ner Nano-Story, Aktie geht rauf von 2 auf 5 $.
Aktie fällt kurz wieder auf 3$
Januar 05: Story geht weiter: CBMX kommt mit ner Burd flu-Story. Kurs steigt auf 9$

Seither ist der Kurs am fallen.

Man sieht es übrigens auch an den Volumen. Immer vor diesen Stories gibt es plötzlich unerklärliche Ausschläge nach oben.

[notebook]

Zufall?

[notebook]

Korrektur: Die besten News kommen immer dann, wenn die Aktie oben ist. Dreimal dürft ihr raten, wer dann kauft.

[notebook]

Wer sagts denn - da haben wir unsere News betreffend der Vogelgrippe - gerade erst rein gekommen:

CombiMatrix Receives Contract from the U.S. Air Force for Microarray Pathogen Detection
Wednesday September 28, 7:00 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Sept. 28, 2005--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) today announced its CombiMatrix Group has received a one year ($338,000) contract from the U.S. Air Force for the development and production of microarrays to detect pathogens that cause upper respiratory infections and pathogens that infect wounds. This contract is the result of a collaborative effort with the Air Force Institute of Occupational Health (AFIOH) that led to the development of a rapid assay and microarray that identifies all forms (serotypes) of influenza A, including bird flu. The first array to be developed under the new contract will identify a number of upper respiratory infections that can cause potentially life threatening diseases (viral and bacterial pneumonia) or lead to pandemic infections (bird flu and SARS).
ADVERTISEMENT


Dr. David Danley, Director of Homeland Security and Defense Programs, said, "This contract with the Air Force expands our relationships with the U.S. military and validates the utility of our microarray technology for military applications. We will utilize this contract to build on previous work with influenza detection and develop microarrays with broader application. Subsequent to our development efforts, the AFIOH will purchase arrays for evaluation and use. CombiMatrix will be able to make these arrays available commercially to other users as well."

"Going forward, we hope to continue expanding our work in areas of interest to our military and national security. These programs include our work with the DOD on a broad detection system for pathogens, our early pre-clinical work on compounds to treat acute exposure to radiation, and now this program with the U.S. Air Force," said Dr. Amit Kumar, President and CEO, of CombiMatrix. "We will continue to monitor the needs of our government as well as corresponding funding opportunities including BioShield."

[notebook]

Ist das jetzt der Startschuss, um einzusteigen?

[notebook]

Der Einstiegszeitpunkt ist m.E. gut. Wir sind nahe der sehr deutlichen Support-Grenze bei 1.60 $ und zudem an einem historischen Tief. Obwohl es von den Zahlen her keine Begründung für dieses Tief gibt.

Grüsse
notebook

[gerega]

Greife nie in ein fallendes Messer.

[notebook]

Die Aktie hab ich nun seit drei Monaten auf der Watchlist. Heute konnt ich nicht widerstehen. Hab mir ein paar für 1.65$ ins Depot gelegt.

Ich bin ja hier mittlerweilen Alleinunterhalter. Aber das ist ja immer so. Sobal ein Titel unter den meistdiskutierten Aktien ist, geht es danach oft runter. Und wenn ne Aktie nicht mehr beachtet wird, liegt man oft richtig. Hab ich Recht? Oder hab ich Unrecht?

[notebook]

Time will tell......

[notebook]

@gerega

Da hast du absolut Recht. Stimme dir zu. Ich konnte trotzdem nicht widerstehen. Ich habe den Aktienkurs in der Vergangenheit mit den herausgegebenen News verglichen. Ich sehe in den heute herausgegebenen News ein Kaufsignal.

Sollte die Aktie die 1.60$ unterschreiten, verkauf ich wieder. Deutliche Confluence von 10 bei 1.60. Das würde mich aber erstaunen. Schau dir mal den P&F Pattern Chart an. Die Aktie ist wirklich an einem unglaublich tiefen Punkt angekommen.

In der Vergangenheit ist der Titel immer dann gesunken, wenn relativ wenig News kamen oder keine speziellen News. Und immer, wenn etwas kam, was hip ist, wie jetzt beispielsweise die Vogelgrippe, ist die Aktie gestiegen.

Ich hab mir noch vor ein paar Tagen gedacht, die kommen sicher mit ner bird-flu story. Und nun ist das tatsächlich eingetreten.

[tomtakker]

Ja, ja kauft nur und greift ins fallende Messer.
Ich kaufe wenn Aktien steigen. Ich kann nur lachen

[notebook]

Hier nochmals die Meldung, die ich als sehr vielversprechend interpretiere:

CombiMatrix Receives Contract from the U.S. Air Force for Microarray Pathogen Detection
Wednesday September 28, 7:00 am ET


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Sept. 28, 2005--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) today announced its CombiMatrix Group has received a one year ($338,000) contract from the U.S. Air Force for the development and production of microarrays to detect pathogens that cause upper respiratory infections and pathogens that infect wounds. This contract is the result of a collaborative effort with the Air Force Institute of Occupational Health (AFIOH) that led to the development of a rapid assay and microarray that identifies all forms (serotypes) of influenza A, including bird flu. The first array to be developed under the new contract will identify a number of upper respiratory infections that can cause potentially life threatening diseases (viral and bacterial pneumonia) or lead to pandemic infections (bird flu and SARS).
ADVERTISEMENT


Dr. David Danley, Director of Homeland Security and Defense Programs, said, " This contract with the Air Force expands our relationships with the U.S. military and validates the utility of our microarray technology for military applications. We will utilize this contract to build on previous work with influenza detection and develop microarrays with broader application. Subsequent to our development efforts, the AFIOH will purchase arrays for evaluation and use. CombiMatrix will be able to make these arrays available commercially to other users as well."

" Going forward, we hope to continue expanding our work in areas of interest to our military and national security. These programs include our work with the DOD on a broad detection system for pathogens, our early pre-clinical work on compounds to treat acute exposure to radiation, and now this program with the U.S. Air Force," said Dr. Amit Kumar, President and CEO, of CombiMatrix. " We will continue to monitor the needs of our government as well as corresponding funding opportunities including BioShield."

[notebook]

Würde mich nicht erstaunen, wenn jetzt in den nächsten Tagen ne Meldung über eine Partnerschaft raus kommt, bei der Combimatrix wieder Gelder zugesprochen bekommt. Das war in der Vergangenheit oft so.

Hinweis: In Indonesien häufen sich die Verdachtsfälle der Vogelgrippe. Im Moment werden 57 Fälle untersucht. Auch wenn es keine Pandemie geben wird und die WHO sicher in einer sehr bildhaften Sprache spricht, so wird die Vogelgrippe m.E. das Thema des kommenden Winters. (Und der kommenden Grippezeit, welche von Oktober bis März dauert)

Grüsse
notebook

[notebook]

@tomtakker

Wegen dem fallenden Messer hab ich einen sehr engen Stop/Loss gesetzt. Wenn die Aktie unter 1.60$ fällt, bin ich wieder raus. Zusammen mit der Courtage hab ich dann 5% verloren. Damit kann ich gut leben.

[notebook]

@tomtakker

Ein gewisses Risiko muss man schon engehen. Bio-Aktien steigen oft in sehr kurzer Zeit sehr stark. Und fallen dann gemütlich über einen relativ langen Zeitraum.

[notebook]

Anbei ein Auszug aus dem Q2-Bericht. Seit Anfang Jahr ist der Kurs nur am sinken.

The CombiMatrix group`s revenues for the second quarter of 2005 were $1,857,000. This represents a gain of 74% over revenues from the first quarter of 2005, and gain of 147% over revenues of the second quarter of 2004. Product and equipment revenues related to CustomArray(TM) were $565,000, which represents an increase of 103% relative to such revenues earned in the first quarter of 2005 and over 1200% greater than such revenues for the second quarter of 2004 ," commented Dr. Amit Kumar, President and CEO of CombiMatrix Corporation.

"Last quarter we achieved our first one million dollar quarter, and during this quarter we nearly achieved our first two million dollar quarter. The CombiMatrix group continues to execute on its plan as our products become accepted in our industry. In addition to the aforementioned sales growth, we made advances in all facets of our business, and began execution of our diagnostics strategy by establishing CombiMatrix Molecular Diagnostics," concluded Dr. Kumar.

[notebook]

[Alex610]

Zeigt sich ein wirklicher Aufwärtstrend bin ich dabei

[notebook]

War vielleicht etwas mutig von mir, bereits jetzt einzusteigen. Ist sicher nicht verkehrt, hier noch abzuwarten. Aber ob das Risiko deswegen kleiner ist? In der Vergangenheit gings immer sehr schnell nach oben. Und dann riskierst du natürlich, dass du bei einem dieser Pseudoanstiege einsteigst, wo es dann sofort wieder runter geht.

Meine Analysen sind natürlich nicht sehr sachlich. Aber mit klassischen Methoden kann man den Aktienkurs der Vergangenheit nicht erklären. Ich konnte jedenfalls keinen Zusammenhang zwischen dem Unternehmensergebnis und dem Aktienkurs feststellen.

[misstexas]

Combimatrix Turnaround-Chance

15.09.2005
Biotech-Report

Für die Experten vom "Biotech-Report" stellt die Aktie von Combimatrix (ISIN US0038812089 / WKN 164630) eine Turnaround-Chance dar.

Combimatrix sei eine Tochter der Acacia Research Corpoartion und habe sich auf die Entwicklung von Nano-Biochips, sogenannte Microarrys, spezialisiert.

Seit 2001 bestehe eine auf 15 Jahre angelegte Kooperation mit Roche. Die Schweizer würden die Chips für diagnostische Zwecke verwenden und zum Teil auch weiterentwickeln und verkaufen. Dafür erhalte Combimatrix Lizenzgebühren und werde an den Verkaufserlösen beteiligt.

Anzeige

Für das US-Militär forsche die US-Firma an Chips, die chemische Kampfstoffe erkennen und anschließend analysieren sollten.

In 2004 habe die Gesellschaft einen Umsatz in Höhe von 19,6 Mio. USD generiert (davon seien 17,3 Mio. USD aus einer Einmalzahlung von Roche). In 2005 dürften ca. 6,9 Mio. USD durch die Bücher gehen, 2006 dann ca. 10 Mio. USD und 2007 20 Mio. USD. Das EPS dürfte wegen hohen Forschungs- und Entwicklungsaufwendungen in diesem Jahr nach Ansicht von Analysten bei -0,44 USD liegen. 2006 werde dann ein EPS von -0,39 USD und 2007 von -0,21 USD geschätzt. Die Gewinnzone solle 2008 erreicht werden. Dann sollte ein Gewinn je Aktie von 0,15 USD erwirtschaftet werden.

Zuletzt habe die Aktie herbe Kursverluste hinnehmen müssen, was nicht zuletzt an der schlechten Stimmung gegenüber Nanotech-Werten gelegen haben dürfte. Doch die Chancen für eine Trendwende stünden nach Ansicht der Experten nicht schlecht: So liege die Marktkapitalisierung des Titels bei nur noch 52 Mio. USD, während das Unternehmen zum Ende des ersten Halbjahres über 55 Mio. USD an Cash-Mitteln verfügt habe.

Sehr risikobereite Anleger spekulieren auf den Turnaround und legen sich einige Stücke der Combimatrix-Aktie als Beimischung ins Depot, so die Experten vom "Biotech-Report".

[notebook]

[notebook]

Obige Grafik zeigt den Hype von Dezember 2003 bis Januar 2004. Zu dieser Zeit war SARS ein grosses Thema.

[ubs36]

Senate approves $4 bln to fight bird flu By Richard Cowan



WASHINGTON (Reuters) - The Senate passed legislation on Thursday to add $4 billion to the U.S. fight against deadly avian flu by stocking up on anti-viral drugs and increasing global surveillance of the disease.

ADVERTISEMENT

The provision, which was attached to an unrelated fiscal 2006 spending bill for the military, faces an uncertain future in the House of Representatives.

The Senate vote came as international organizations urged the United States and other countries to be more aggressive against the avian flu outbreak.

Sen. Ted Stevens (news, bio, voting record), an Alaska Republican shepherding the defense spending bill through the Senate, said he would try to block the avian flu provision. His next opportunity will be when Senate and House negotiators meet to work out a compromise on the defense spending bill. That meeting has not been set.

Avian flu among flocks in Asia has been growing for several years and outbreaks have been spotted in parts of Russia. So far, 65 people in Asia who are thought to have had close contact with infected birds have died since 2003.

Scientists fear a mutation of the H5N1 virus could make it transmissible among humans, sparking a worldwide epidemic that could kill millions of people.

"It`s the midnight hour. We have to get moving on it now, not next year, not after some study group in the White House bangs this thing around for another three months," said Sen. Tom Harkin (news, bio, voting record), an Iowa Democrat.

Harkin, with the backing of Senate Minority Leader Harry Reid, a Nevada Democrat, wants the government to spend nearly $3.1 billion to stockpile enough doses of an anti-viral drug for half the U.S. population.

Harkin said there were only 2 million doses on hand now, enough for 1 percent of the population.

`WE OUGHT TO WAIT`

Two anti-viral drugs have been shown to ease avian flu symptoms and possibly prevent it. Switzerland`s Roche Holding AG makes Tamiflu, known generically as oseltamivir, and GlaxoSmithKline makes Relenza, or zanamivir.

It is unclear how quickly pharmaceutical firms could fill a U.S. order for about 150 million doses.

Under the Senate plan, other funds would be used to increase global surveillance of the disease, increase spending on a vaccine and help states and cities prepare for a large outbreak.

Stevens argued that avian flu "has not yet become a threat to human beings," and added, "We ought to wait for the scientists to tell us what needs to be done."

A U.N. official said on Thursday a worldwide drive would be launched to combat a pandemic that could kill half of those infected.

Senate Majority Leader Bill Frist of Tennessee, a surgeon, said he called on Health and Human Services Secretary Michael Leavitt to complete a national preparedness plan.

[notebook]

- Die Durchschnittsvolumen sind weiter steigend.
- Wir haben neu bei 1.66$ eine deutliche Confluence von 17. Das bedeutet, dass bei 1.66$ ein starke Supportlinie ist. Man kann das auch sehr gut an den Volumen beobachten. Preise unter 1.66$ werden sofort zum Kauf genutzt.
- Die Stimmung in den Ami-Boards hat gedreht. Kaufempfehlungen überwiegen deutlich. Auch die Frequenz der Postings hat zugenommen.

Grüsse
notebook

[notebook]

Jeden Tag, wo die Volumen nicht absinken und der Kurs hält, wird deutlicher, dass ein Turnaround ansteht. Die steigenden Volumen zeigen das aufkommende Interesse.

Persönliche Meinung:
Risiko: Griff in ein fallendes Messer
Chance: Turnaround

Meines Erachtens sollte man nicht zu lange warten. Wenn die Anleger realisieren, dass der Turnaround bevorsteht, geht die Aktie sofort nach oben. Das Risiko eines "fallenden Messers" kann mit einem engen Stop/Loss begrenzt werden.

Grüsse
notebook

[ubs36]

Marktkapitalisierung: 52 Mio $ !
Cash: 54 Mio $ !

@notebook
Ich hoffe du hast dich schon ordentlich eingedeckt. Ich werd mir jedenfalls noch ein paar ins Depot legen.

[misstexas]

http://www.combimatrix.com/pr/012904.pdf

http://www.combimatrix.com/pr/031704.pdf

[notebook]

Die Konkurrenz schläft nicht
Der Combimatrix-Jahreschart


Während Affymetrix auf das Reich der Mitte setzt, konzentriert sich Combimatrix auf Japan. In Zusammenarbeit mit Inter Medical will das Unternehmen künftig seine Genchips auf dem japanischen Markt etablieren. Ähnliche Kooperationen bestehen seit längerem auch für den australischen und den neuseeländischen Markt. Einer ausgeklügelten Technologie - Combimatrix kann seine Biochips genau auf die Bedürfnisse der Kunden ausrichten - ist es zu verdanken, dass man nicht nur im medizinischen Bereich punkten kann. Für die US-Armee wird beispielsweise ein Biochip zum Aufspüren von Kampfstoffen entwickelt. Aber auch die Kooperation mit Roche könnte dem Unternehmen künftig frisches Kapital zuführen. Der Pharmariese setzt die Biochips von Combimatrix in der Medikamentenforschung ein. Aufgrund der jungen Technologie hinkt man Affymetrix jedoch noch hinterher. Im ersten Quartal 2005 erzielte Combimatrix einen Umsatz von 1,07 Millionen Dollar. Der Verlust betrug 4,9 Millionen Dollar.

[notebook]

Auszug aus "Der Aktionär" vom 23.05.05:

Combimatrix

ISIN US0038812089
Kurs am 03.06.2005: 2,25€
Empfehlungskurs: 2,33€
Ziel : 5,00€
Stopp : 1,65€
Chance/Risiko: 5/5

Das ging ja ziemlich daneben. Wer der Kaufempfehlung gefolgt ist, hat ordentlich Buchverluste eingefahren. Vielleicht ist ja jetzt ein günster Zeitpunkt, um enzusteigen?

[misstexas]

CombiMatrix Introduces Its CustomArray 4X2K Line Of Microarrays

Acacia Research Corporation announced today that its CombiMatrix group has expanded its product line to include the CustomArray 4X2K. This product contains four independent 2000-feature microarrays on a single CustomArray.

As with all CustomArray products, the 4X2K offers complete array customization, user control of probe design, and the ability to modify microarray design at any time. It delivers high sensitivity, throughput, and ease of use for gene discovery, pathway research, and molecular characterization of disease.

"The DNA-array market has various segments," said Michael Tognotti, Vice President of Sales and Marketing of CombiMatrix. "One is a segment where customers desire low-cost arrays and do not need a large number of features per array. The 4X2K, with four 2000-feature microarrays per semiconductor chip, is ideally suited to that segment. This new product maintains CombiMatrix`s margins, which is based on price per semiconductor chip, but greatly reduces research costs for customers, which is based on price per microarray. This is an excellent addition to our product line and a great complement to the CustomArray 12K used by customers who desire more features."

The 4X2K is priced starting at $99 per 2000-feature microarray. The 4X2K will be marketed to the pharmaceutical, biotechnology, diagnostic, academic, and government sectors.

COMBIMATRIX CUSTOMARRAYS

CustomArrays are semiconductor-based arrays (approx. 1 cm squared) integrated onto a standard 1" x 3" slide format. CustomArrays contain in situ synthesized oligonucleotides, prepared using CombiMatrix`s patented virtual-flask technology. Sensitivity and performance metrics are available from the company`s web site and at http://www.customarray.com.

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 32 patent portfolios, which include over 120 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies and Acacia Research-CombiMatrix are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at http://www.acaciaresearch.com.

[misstexas]

Other Headlines from CombiMatrix ...
- CombiMatrix and Cyrano Sciences Collaborate on the Development of Nanotechnology Based Chemical Sensors
- CombiMatrix Names Nanotechnology Leader F. Mark Modzelewski to Its Scientific Advisory Board
- CombiMatrix`s Partner Nanomaterials Discovery Corporation Issued Key Nanotech Patent
- CombiMatrix and Nanomaterials Discovery Corporation deliver a prototype workstation for the combinatorial discovery and development of new nanomaterials
- CombiMatrix`s CEO Dr. Amit Kumar Appointed to Board of the NanoBusiness Alliance

More Products Headlines ...
- Nanotechnology in future cars
- Intermec Introduces MEMS Nanotechnology to Supply Chain Laser Scanning
- Nanergy Inc. Issues Manufacturing Order For First Product and Obtains Financing
- Authentix Offers Complete Brand Protection Inside and Out
- Nanotechnology Innovation Enables Recovery and Reuse of Spilled Oil

[notebook]

[McMoneysac38]

Sieht ja vielversprechend aus.

[McMoneysac38]

In den letzten Tagen hatten wir auch steigende Volumen! Hat schon jemand den Chart angeschaut?

[McMoneysac38]

http://www.nsti.org/press/PRshow.html?id=395

Und dann kam kürzlich ne Meldung betreffend eines neuen Auftrages rein. Die arbeiten an einem Bioschutzschild gegen eine mögliche Pandemie. Beispielsweise die Vogelgrippe.

[McMoneysac38]

Leute, ich die Antwort, weshalb der Kurs so stark gesunken ist.

http://losangeles.bizjournals.com/losangeles/stories/2005/09…

Acacia Research Corp. will sell CombiMatrix common stock and warrants in a registered direct offering to a group of accredited investors, the company said in a release Friday.
[0]

Under the terms of the deal, Acacia will sell 6.4 million shares at $1.65 per share and offer investors five-year warrants for an additional 1.6 shares of common stock at $2.40 per share.

Acacia Research-CombiMatrix has 31.2 million shares outstanding.

Piper Jaffray & Co. acted as the placement agent for the transaction, the company said.

[McMoneysac38]

Damit dürfte wohl klar sein, dass der Boden bei 1.65 $ ist.

[McMoneysac38]

Und weils so schön ist, gleich nochmal: Leute, ich hab die Antwort, weshalb der Kurs so stark gesunken ist.

http://losangeles.bizjournals.com/losangeles/stories/2005/09…

Acacia Research Corp. will sell CombiMatrix common stock and warrants in a registered direct offering to a group of accredited investors, the company said in a release Friday.
[0]

Under the terms of the deal, Acacia will sell 6.4 million shares at $1.65 per share and offer investors five-year warrants for an additional 1.6 shares of common stock at $2.40 per share.

Acacia Research-CombiMatrix has 31.2 million shares outstanding.

Piper Jaffray & Co. acted as the placement agent for the transaction, the company said.

[misstexas]

Ich hab mir letzte Woche ein paar ins Depot gelegt. Da hatte ich ja richtig Glück.

[McMoneysac38]

Hallo misstexas

So früh schon am PC? Ich hab leider noch nicht investiert. Aber heisst doch? Besser spät als nie.

[misstexas]

Tolle Recherche, dass mit den 1.65$. Im Aktionär wurde die Aktie bei 2.30 Euro zum Kauf empfohlen. Mit Kursziel 5 Euro !

[McMoneysac38]

Der Aktionär ist ein Pusherblättchen ! Da lach ich nur. Aber eines ist sicher, der Kurs wurde nur wegen den Investoren so tief gehalten.

[McMoneysac38]

Werd jetzt mal ein paar Recherchen anstellen. Wie es aussieht, scheinen hier die richtigen Leute dran zu sein.

[McMoneysac38]

In den letzten Tagen wurde ja hier schon einiges zusammen getragen.

[misstexas]

[McMoneysac38]

Wie es aussieht, ist ja auch Roche ein Partner. Hast du dir mal die Beteiligungen angesehen?

[McMoneysac38]

Ich glaub das einfach immer noch nicht. Das muss ich einfach reinstellen:

Friday, September 16, 2005

NEWPORT BEACH--- CombiMatrix Group to Receive $10.5 Million from Acacia Research Registered Direct Offering
Posted: 9/16/2005 @ 6:47 AM

Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) today announced that it has obtained commitments to purchase approximately $10.5 million of its Acacia Research-CombiMatrix common stock in a registered direct offering. Under the terms of the transaction, Acacia will sell approximately 6.4 million shares of its Acacia Research-CombiMatrix common stock at $1.65 per share to a select group of accredited investors and grant to such investors five year warrants for the purchase of an aggregate of approximately 1.6 million shares of common stock at an exercise price of $2.40 per share. Piper Jaffray & Co. Acted as exclusive placement agent for the transaction.

[McMoneysac38]

Das ist doch einfach sowas von logisch, dass der Kurs sinkt. Und die Idioten hier stellen tausend Fragen wegen den Volumen!

Zum Glück hab ich das noch gelesen.

[misstexas]

[misstexas]

@mcmoneysac

Was sagst du denn zu nachfolgendem Rating?

http://www.newratings.com/analyst_news/article_939884.html
CombiMatrix downgraded to "Hold"

Wednesday, July 27 , 2005 1:52:29 PM ET
Brean Murray

NEW YORK, July 27 (newratings.com) - Analysts at Brean Murray downgrade CombiMatrix (ticker: CBMX) from Buy to Hold.

[McMoneysac38]

Die hätten besser geschrieben: Von buy auf sell !

Seither gings ja mehr als 1/3 runter! Wenn die Investoren Aktien zu 1.65$ bekommen, dürfte klar sein, dass dies der Boden ist.

[ubs36]

Hallo Geldsack

Wie gehts? Überrascht mich nicht, dass du dich hier rumtreibst. Überall dort, wo Geld ist?

Es gibt auch noch andere Werte im Leben.

[McMoneysac38]

Stimmt - All die Dinge, die man sich mit Geld kaufen kann, sind auch wichtig.

[McMoneysac38]

@misstexas

Ich halte nicht viel von Analysten. Weiss aus eigener Erfahrung, wie die arbeiten. Hab dir trotzdem ne Analystenempfehlung rausgesucht. Eigentlich hab ichs kopiert. Stand schon im Thread:

Combimatrix Turnaround-Chance

15.09.2005
Biotech-Report

Für die Experten vom " Biotech-Report" stellt die Aktie von Combimatrix (ISIN US0038812089 / WKN 164630) eine Turnaround-Chance dar.

Combimatrix sei eine Tochter der Acacia Research Corpoartion und habe sich auf die Entwicklung von Nano-Biochips, sogenannte Microarrys, spezialisiert.

Seit 2001 bestehe eine auf 15 Jahre angelegte Kooperation mit Roche. Die Schweizer würden die Chips für diagnostische Zwecke verwenden und zum Teil auch weiterentwickeln und verkaufen. Dafür erhalte Combimatrix Lizenzgebühren und werde an den Verkaufserlösen beteiligt.

Anzeige

Für das US-Militär forsche die US-Firma an Chips, die chemische Kampfstoffe erkennen und anschließend analysieren sollten.

In 2004 habe die Gesellschaft einen Umsatz in Höhe von 19,6 Mio. USD generiert (davon seien 17,3 Mio. USD aus einer Einmalzahlung von Roche). In 2005 dürften ca. 6,9 Mio. USD durch die Bücher gehen, 2006 dann ca. 10 Mio. USD und 2007 20 Mio. USD. Das EPS dürfte wegen hohen Forschungs- und Entwicklungsaufwendungen in diesem Jahr nach Ansicht von Analysten bei -0,44 USD liegen. 2006 werde dann ein EPS von -0,39 USD und 2007 von -0,21 USD geschätzt. Die Gewinnzone solle 2008 erreicht werden. Dann sollte ein Gewinn je Aktie von 0,15 USD erwirtschaftet werden.

Zuletzt habe die Aktie herbe Kursverluste hinnehmen müssen, was nicht zuletzt an der schlechten Stimmung gegenüber Nanotech-Werten gelegen haben dürfte. Doch die Chancen für eine Trendwende stünden nach Ansicht der Experten nicht schlecht: So liege die Marktkapitalisierung des Titels bei nur noch 52 Mio. USD, während das Unternehmen zum Ende des ersten Halbjahres über 55 Mio. USD an Cash-Mitteln verfügt habe.

Sehr risikobereite Anleger spekulieren auf den Turnaround und legen sich einige Stücke der Combimatrix-Aktie als Beimischung ins Depot, so die Experten vom " Biotech-Report" .

[McMoneysac38]

Die haben alle keine Ahnung. Ist aber immer amüsant, zu lesen, was so die Konkurrenz macht.

[ubs36]

Du übertreibst mal wieder total.

[McMoneysac38]

Der Herr Kollege weiss es wieder mal besser. Wieso treibst du dich denn hier rum? Hat dich deine Frau verlassen?

[McMoneysac38]

Heute ist Weihnachten und Morgen kauf ich mir was Schönes.

[misstexas]

@mcmoneysac

Würdes du denn eher in USA oder in Frankfurt kaufen?

[McMoneysac38]

girl, kauf dort, wo es mehr Volumen hat.

[McMoneysac38]

Der Artikel ist zwar schon etwas älter, aber die Bedrohung ist ja aktuell nicht weniger dramatisch.

Murray Secures $3 Million to Help American Soldiers Detect Chemical and Biological Hazards on the Battlefield
Murray meets with employees and tours CombiMatrix Facility in Mukilteo

For Immediate Release: Wednesday, December 17, 2003

(SEATTLE, WA) - Today, U.S. Senator Patty Murray (D-Wash) visited CombiMatrix Corp. in Mukilteo, Washington. The company is developing a technology that will allow American troops to instantly identify chemical and biological hazards on the battlefield.

Murray, as a member of the Senate Appropriations Committee, has worked over the years to invest in new technologies to protect American troops. Murray secured $3 million in the Fiscal Year 2004 Defense Appropriations Act and $3.6 million in Fiscal Year 2003 to develop a portable system to allow troops to continuously detect multiple chemical and biological threat agents in the field.

“Our soldiers risk their lives for us, and they deserve accurate, instant information on the threats they face in combat,” Murray said. “I’m proud that a Washington state company is on the cutting edge of this new technology that will protect our troops.”

Amit Kumar, the CEO of CombiMatrix, said, "Sen. Murray is a leader both in promoting the development of Washington as a biotechnology center and in ensuring that America possesses the systems needed for defense against biological and chemical threats. CombiMatrix was thrilled at the chance to show the Senator how we are supporting her work towards both of these goals."

This new capability will be a dramatic improvement over existing technology because troops will not have to wait for samples to be analyzed in a lab. In addition, unlike existing testing equipment that can only be used once, this new technology will provide continuous monitoring.

Murray toured the facility today to congratulate CombiMatrix workers and local suppliers on their efforts to protect American troops.

[McMoneysac38]

09/06/2005 - NEWS: CombiMatrix to offer low-cost microarrays for certain markets

FaxWatch - Acacia Research Corp. said its CombiMatrix group now offers the CustomArray 4X2K line of microarrays, which contain four independent 2,000-feature microarrays on a single CustomArray.

According to the company, the 4X2K offers complete array customization, user control of probe design and the ability to modify the microarray design at any time, while delivering high sensitivity, throughput and ease of use for gene discovery, pathway research and molecular characterization of disease.

Michael Tognotti, CombiMatrix`s vice president of sales and marketing, said the 4X2K serves the segment of the microarray market that desires low-cost arrays with a smaller number of features per array. "This new product maintains CombMatrix`s margins, which is based on price per semiconductor chip, but greatly reduces research costs for customers, which is based on price per microarray," he added.

The product will be marketed to the pharmaceutical, biotechnology, diagnostic, academic and government sectors, the company said.

[McMoneysac38]

Da hab ich tatsächlich noch was gefunden, was abgesehen von den 1.65$ interessant ist.

War Over SARS: Who Gets the Patent?

Barbara Carroll, NewsMax.com
Friday, May 9, 2003

The federal government has applied for a patent on the SARS coronavirus. This decision was made to keep the deadly contagion from private labs that might prevent information from free global use.

"Depending on who held the patent, it would tend to lock out competitors," said Dr. Julie Gerberding, director of the Centers for Disease Control and Prevention.

The CDC`s goal is to keep the virus available for appropriate labs to use for research, diagnostic tests and the making of a vaccine. "We are very cautious that people applying for the virus have appropriate containment safety environments for the handling of the virus," she said.

There are concerns about the use of SARS for bioterrorism. An infectious disease from the family of the common cold that can live on surfaces at least 24 hours can be a deadly weapon in the wrong hands.

Researchers are not being sent the live virus but a "genetically engineered piece of the virus," Gerberding said during a briefing Thursday. Because the live virus should be handled only in a level 3 containment environment, this limits the number of labs and countries with research facilities that should have access to the living virus.

The British Columbia Cancer Agency has also applied for a patent on the genetic sequencing of the virus. Dr. Marco Marra, the scientist most credited with reading the genetic code, agrees that the virus code should be available to the scientific community.

CombiMatrix Inc., a U.S. biotechnology company which is part of Acacia Research Corp., has produced dozens of molecules that could eventually be used in drugs to fight the SARS epidemic. It has made DNA chips based on the genetic makeup of the virus responsible for SARS which have been sent to USAMRIID and the National Institute of Allergy and Infectious Diseases among other labs. These labs will perform initial screening to find which ones can be developed into potential drugs to fight SARS.

The University of Hong Kong has filed for a patent on the SARS virus through its agency Versitech Ltd.

Since 1980, the U.S. Patents and Trademark Office has been allowed by a Supreme Court ruling to patent genes. This has been a subject of debate for more than two decades.

More than 500,000 patents have been applied for on genes or gene sequences, and the list is expanding. With molecular research just scratching the surface of possibilities, countries and companies are elbowing to grab the glory and the money.

After the public announcement by CombiMatrix, the subsidiary`s tracking stock rose 20 percent. Scientists share in the monetary rewards when a gene is patented. The companies and governments who own a gene patent can use the money earned to put back into research. Private companies want a return on their investment, so a lab such as CombiMatrix doesn`t want to put money into a project for which it has no patent protection.

The World Health Organization is taking a neutral position. "What we care about is the international collaboration continues to function," WHO spokesman Dick Thompson said to the Associated Press. "Patents, they don`t really concern us."

It can take about two years for a patent to be awarded.

[McMoneysac38]

Fall jemand den ganzen Text lesen möchte.

http://www.newsmax.com/archives/articles/2003/5/9/132657.sht…

[misstexas]

@mcmoneysac

CombiMatrix Inc., a U.S. biotechnology company which is part of Acacia Research Corp., has produced dozens of molecules that could eventually be used in drugs to fight the SARS epidemic.

Der Artikel ist aus dem Jahre 2003 !

Wieso stellst du den hier rein?

[McMoneysac38]

Such dir deine Antwort selber aus.

[misstexas]

[McMoneysac38]

Bird flu `could kill 150m people`
A man prepares to release race pigeons in Jakarta, Indonesia
Experts fear birds will carry the virus across borders
A flu pandemic could happen at any time and kill between 5-150 million people, a UN health official has warned.

David Nabarro, who is charged with co-ordinating responses to bird flu, said a mutation of the virus affecting Asia could trigger new outbreaks.

"It`s like a combination of global warming and HIV/Aids 10 times faster than it`s running at the moment," Dr Nabarro told the BBC.

But the World Health Organisation has distanced itself from the figure.

The WHO spokesman on influenza, Dick Thompson, told a news conference in Geneva that the WHO`s official estimate of the number of people who could die was between two million and 7.4 million.

QUICK GUIDE

Bird flu

"There is obvious confusion, and I think that has to be straightened out. I don`t think you will hear Dr Nabarro say the same sort of thing again," Mr Thompson said.

Bird flu has swept through poultry and wild birds in Asia since 2003.

It has killed huge numbers of birds and led to more than 60 human deaths.

Prepared for worst

"The range of deaths could be anything between 5m and 150m," the UN`s new co-ordinator for avian and human influenza said in his BBC interview.

Dr Nabarro said he stood by the figure drawn from the work of epidemiologists around the world.

[misstexas]

Und was hat das mit Combimatrix zu tun? Der Artikel aus dem Jahre 2003 bezieht sich auf SARS!

[McMoneysac38]

Man findet ja nicht täglich ne Goldgrube. Da will ich mal nicht so sein.

[McMoneysac38]

First: "CombiMatrix Inc., a U.S. biotechnology company which is part of Acacia Research Corp., has produced dozens of molecules that could eventually be used in drugs to fight the SARS epidemic."
Den Text hast du ja selber noch reingestellt.

Second: "Combimatrix is working on a bioshield"
Die Meldung ist aktuell! Combimatrix arbeitet an einem Bioshield im Hinblick auf eine mögliche Pandemie.

girl, das ist alles Quatsch. Wer glaubt den schon an eine Pandemie.

Hauptsache die Kurse steigen und ich kann mir wieder was Schönes kaufen.

[ubs36]

Also für so unwahrscheinlich halte ich ne Pandemie nun auch wieder nicht.

[ubs36]

@all

Gewisse Leute schrecken vor gar nichts zurück.

[McMoneysac38]

Du bist ja immer noch hier?

Es geht doch nicht um die Pandmie oder die Vogelgrippe. Die Aktie bietet super Einstiegschancen. Aktien wurden zu 1.65$ an Investoren verkauft.

[McMoneysac38]

Wenn da jetzt noch ne Pandemie-Fantasie rein kommt.....

[ubs36]

Wenn ne Pandemie rein kommt, dürfte die Frage eher sein, ob du das überlebst.

[ubs36]

WHO Tries to Allay Bird Flu Fears


September 30, 2005 10:58:28 PM PST


The World Health Organization moved Friday to revise alarming predictions that a pandemic stemming from the bird flu virus ravaging parts of Asia could kill as many as 150 million people.

The U.N. health agency was deluged with inquiries after Dr. David Nabarro — named Thursday as the U.N. coordinator for avian and human influenza — cited the number during a news conference at the U.N.`s New York headquarters.

While WHO`s flu spokesman at the agency`s Geneva headquarters did not say the 150 million prediction was wrong, he emphasized that 7.4 million deaths is a more realistic estimate.

Scientists have made predictions ranging from less than 2 million to 360 million. Last year, WHO`s chief for the Asia-Pacific region predicted 100 million deaths, but until now that was the highest figure publicly mentioned by a WHO official.

"We`re not going to know how lethal the next pandemic is going to be until the pandemic begins," WHO influenza spokesman Dick Thompson said Friday.

"You could pick almost any number" until then, he said, adding that WHO "can`t be dragged into further scaremongering."

Experts agree there will certainly be another flu pandemic — a new human flu strain that goes global. However, it is unknown when or how bad that global epidemic will be.

It also is unknown whether the H5N1 bird flu strain circulating in Asian poultry now will be the origin of the next pandemic. But experts are tracking it just in case, and governments across the world are preparing themselves for such a possibility.

Two factors will have a major influence on how many people will die from the next flu pandemic, experts say. One is the attack rate — the proportion of the population that become infected. The other is the death rate, or the proportion of the sick who die.

Normal seasonal flu viruses have an attack rate of between 5 percent and 20 percent, but a death rate of less than 1 percent. Between 250,000 and 500,00 die from flu every year, according to WHO.

Based on evidence from the three pandemics that occurred during the 20th century, scientists have determined that pandemic flu strains tend to infect between 25 percent and 35 percent of the population.

The worst death rate was seen in the 1918 Spanish flu pandemic. That killed 2.6 percent of those who got sick, or about 40 million people.

The other two pandemics were gentler. The 1957 one killed 2 million and the most recent, in 1968, killed 1 million.

Forecasts that change the assumed attack rate or death rate will yield different predictions. Other assumptions, such as whether anti-flu drugs will work against the virus, also would change the figures.

WHO said Friday it considers the most likely scenario to be a death toll of between 2 million and 7.4 million people.

"That`s because we looked at what happened in the 1918 pandemic. That caused the greatest number of deaths ever recorded from an infectious disease in a single year, by far. More than the black plague, more than any other infectious disease," Thompson said.

"That was an extreme of an already rare event. Pandemics normally have more modest death rates."

When the U.N. health agency advises countries on how to prepare for the next pandemic, it uses the most moderate scenario likely to happen. It does not mean that a more exaggerated scenario cannot happen, only that it is less likely, Thompson said.

"There is a limited amount of public health money available to countries and we have to give them the best guidance on how to spend that money," he said.

The H5N1 strain of bird flu has swept through poultry populations in large swaths of Asia since 2003, jumping to humans and killing at least 65 people — more than 40 of them in Vietnam — and resulting in the deaths of tens of millions of birds.

Most human cases have been linked to contact with sick birds. But WHO has warned the virus could mutate into a form that spreads easily among humans — changing it from a bird virus to a human pandemic flu strain.

[ubs36]

@Geldsack

Wenn solche Meldungen raus kommen, bekomm ich ne Gänsehaut. Die versuchen nur ne Massenpanik zu vermeiden. Dabei haben sie vorher monatelang von 150 Millionen Toten und mehr gesprochen.

Tja, und nun kommst du mit Combimatrix und denkst nur ans Geld.

[McMoneysac38]

[McMoneysac38]

Schade, dass es kein Smilie gibt, mit nem Dollarzeichen drauf.

[McMoneysac38]

[McMoneysac38]

[misstexas]

Ich denke das Wichtige ist doch, dass wir nun den Boden erreicht haben. Die Investoren erhalten die Aktien zu 1.65$!

[misstexas]

Thread: COMBIMATRIX ! Unentdeckte Vogelgrippe-Aktie !

Ich hab mal einen Thread eröffnet zum Thema Vogelgrippe. Wenn man hier nicht Aktien an Investoren verkauft hätte, so wäre die Aktie sicher schon lange über 2$. Bei dem Umfeld ! Die Angst vor einer Pandemie wächst.

[ubs36]

Interessant ist übrigens auch der Vergleich mit Affymetrix. Affymetrix ist ja ein direkter Konkurrent, wobei Combimatrix und Affymetrix auf unterschiedlichen Märkten agieren.

[ubs36]

[ubs36]

Sieht noch vielversprechend aus. Muss die Aktie am Montag mal eingeben.

[ubs36]

[ubs36]

Acacia hat sich letzte Woche hervorragend entwickelt. Da müsste doch Combimatrix nachziehen?

[ubs36]

Acacia ist letzte Woche um 20% gestiegen.

@Geldsack
Sowas dürfte dich doch interessieren?
Hast Post bekommen.

[Herostratos]

der Abwärtstrend ist doch noch vollkommen intakt

[ubs36]

@herostratos
Es ist sicher nicht verkehrt, hier noch zu warten. Allerdings hat der Chart letzte Woche von bearish auf neutral gewechselt. Zudem wurden Aktien an Investoren zu 1.65$ verkauft. Deshalb halte ich die momentanen Kurse für eine günstige Einstiegsgelegenheit. Meine Erfahrung sagt mir, dass die Investoren sicher nicht ungünstige Konditionen erhalten.

Darf ich dich fragen, was für eine professionelle Chartsoftware du benutzt?

[ubs36]

Vorerst letzte Meldung für heute, hab leider viel zu tun:

Hab mir das nochmals angesehen. Am 16.09.05 kam die Meldung, dass Aktien zu 1.65$ an Investoren gehen. Diese Meldung könnt ihr selber nachlesen.

Wer davon vorher wusste, hat seine Aktien verkauft. Zudem wurden die Aktien geshortet. Das Prinzip ist ganz einfach. Wenn man vor dem 16.09.05 weiss, dass Aktien zu 1.65$ gehen, ist ja klar, dass der Kurs sinken wird. Also leiht man sich Aktien bei der Bank und verkauft sie, um sie später zu einem niedrigeren Kurs zurückzukaufen.

Es ist gut möglich, dass wir noch vereinzelt Kurstaucher sehen werden. Grundsätzlich sehe ich aber zwei Punkte, die für einen Kauf sprechen:
1. Wenn man shortet, muss man die Aktien auch wieder zurückkaufen. Man hat sich ja die Aktien nur geliehen.
2. Ich gehe davon aus, dass die Investoren sicher vorteilhafte Konditionen erhalten. Zumindest werden diese die Aktien sicher nicht unter 1.65$ verkaufen.

Mögliche Szenarien:
Der Kurs wird in den nächsten Wochen auf über 2$ steigen. Dann kommt es zu ersten Gewinnmitnahmen. Danach steht einem Kursziel von 3$ nichts mehr im Wege. Das veröffentlichte Kursziel von "Der Aktionär" von 5 Euro halte ich für sehr optimistisch.

Beste Grüsse und schönen Tag noch

[notebook]

Bin heute wieder raus. Hab bei 1.65 vor ein paar Tagen gekauft. Kauf nur Aktien, die steigen. War der Ansicht, dass dies der Boden ist. Nun haben wir abnehmende Volumen. Das gefällt mir gar nicht.

Grüsse
notebook

[ubs36]

Man soll nichts überstürzen. Abwarten.

[hasi22]

Nun scheint der Boden gebildet, habe heute gekauft

[notebook]

mmmmhhh. Im Moment scheint eh alles zu steigen. Könnte sein. Ich warte noch.

[notebook]

Bei Cbmx hab ich irgendwie das Gefühl, dass da noch Einstiegsgelegenheiten bei so um 1$ kommen werden. Ich trau der Sache noch nicht so ganz.

[notebook]

Heute startet die Party.

[Aptamilla]

[posting]18.453.782 von notebook am 26.10.05 15:08:07[/posting]Auf Deutsch bitte(News)?

[neatneatneat]

CombiMatrix Announces Availability of Comprehensive Influenza Array and Service; Array Can Identify All Strains of Influenza A, Including The H5N1 Bird Flu.

Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix Group has launched a new comprehensive influenza DNA microarray as well as services for the typing of influenza strains. CombiMatrix`s Influenza Microarray is now a member of the CatalogArray(TM) product line and can detect and accurately type flu strains using a protocol that requires less than four hours start to finish. This new microarray can identify H5N1 bird flu as well as all other strains of Influenza A. It can also provide information on mutations and novel strains of flu not yet seen. It is designed to work on samples from humans as well as from birds, pigs, horses, dogs, and various other animals. Strains of Influenza A include H5N1 bird flu, which so far is resulting in 50% mortality rate among people who are infected; the 1918 strain, which killed an estimated 50 million people; the 1957 "Asian" flu and the 1968 "Hong Kong" Flu, which both caused pandemics; the 1976 "Swine" flu; and the current dog flu. The Influenza Microarray provides very-high-resolution genotype information on any given flu strain as well as information on novel strains of flu produced by rapid mutation or recombination between multiple strains of flu.


This system is available to the flu researcher as a tool or as a service from CombiMatrix. This system is also being developed as a field-deployable biodetector using electrochemical techniques for analysis. This array can be employed as an adjunct to existing technology, to type difficult or ambiguous samples of flu, or to study genetic drift in a flu virus as it moves through a population. Knowledge of the exact strain, origin of the strain, and probable characteristics of the virus are critical for disease surveillance and limiting the spread of the disease.

The current, major public health concern is the avian H5N1 virus, which has potential for further recombination with common human strains (such as H3N2) or other non-human strains common in avian populations (H7 and H9 strains). The current strain, which was initially found in birds in East Asia, has only infected humans who have been exposed to infected birds. Through the migration of birds, this strain has now been seen in other geographic regions and is expected to reach all continents. Should the virus become transmissible from human to human, it has the potential to cause a world-wide pandemic. In addition, many strains exhibit resistance to drugs that are used to treat influenza, and this array may identify these subtypes. Therefore, identification of the strain and subtype and accurate sequence information could be crucial to treatment of infected individuals as well as develop appropriate vaccines.

"Rapid response and accurate information are the absolute key criteria when dealing with a highly transmissible virus, such as influenza," said Dr. Amit Kumar, President and CEO of CombiMatrix. "CombiMatrix`s platform is ideal for the rapid development of new tools to rapidly identify emerging diseases."



ABOUT ACACIA RESEARCH CORPORATION



Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 33 patent portfolios, which include over 120 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, high resolution optics, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Quelle: BUSINESS WIRE

[puddy66]

notebook ,schade ich bin dabei! man sollte nicht immer zu lange warten!!!!!!!!

[fritzchenI]

kann die heutige News jemand mir übersetzen?

[puddy66]

heute geht die party weiter!! schade das die amis gestern
abend noch ca.20 % abgegeben haben!

heute gehts weiter richtung norden!!

[notebook]

Ich hab euch doch schon lange gesagt, die kommen mit ner burd flu story.

[hasi22]

Nachbörslich CBMX

Last Trade: 1.95 4:02PM ET
After Hours Change: 0.05 2.63%

in froher Erwartung gute Nacht an Alle

[DagobertDuck57]

News!!!!!!!!!!!!!!!
11/14/2005 11:23:34 PM
Renowned Pathologist Dr. Scott W. Binder Joins CombiMatrix Molecular Diagnostics Scientific Advisory Board

Acacia Research Corporation announced today that Dr. Scott W. Binder, M.D. has joined CombiMatrix`s wholly owned subsidiary, CombiMatrix Molecular Diagnostics (CMD), as a member of its Scientific Advisory Board. Dr. Binder is a renowned Dermatopathologist and an internationally known expert in skin diseases with a specialty in pigmented lesions and lymphoid lesions of the skin.

Dr. Binder is a Professor of Clinical Pathology and Dermatology, Chief of Dermatopathology, and Director of Pathology Outreach Services at the David Geffen School of Medicine at UCLA. He is also the founder and Director of one of the few Dermatopathology fellowship training programs in the state of California. Dr. Binder brings a wealth of clinical experience to diagnostic dermatopathology and his comprehensive consultative reports are widely sought.

"We recognize the importance of having leading experts in cancer research on our team as we move toward the commercialization of our cancer diagnostics," stated Matthew Watson, Chief Executive Officer of CMD. "Dr. Binder is well-known and respected and brings a wealth of real-world experience to CMD`s Scientific Advisory Board. We look forward to the contribution of his insight and guidance as we begin to launch our diagnostic services."

"I look forward to providing scientific and clinical insight to CMD as they continue developing truly innovative, molecular diagnostic tests for a variety of cancers," said Dr. Binder.

A native of Chicago, Dr. Binder attended the University of Chicago, obtaining a B.A. and an M.D. from the University of Chicago Medical School. He completed his residency at the Department of Pathology and Laboratory Medicine at UCLA and was a Fellow with James Graham, M.D., at the Scripps Clinic and Research Institute in La Jolla, CA. He then completed a Preceptorship with A. Bernard Ackerman, M.D. at New York University. Drs. Graham and Ackerman are internationally-recognized leaders in the field of dermatopathology. Dr. Binder is board certified in Anatomic Pathology, Clinical Pathology, and Dermatopathology

[pes05]

Wird Zeit das der Kurs sich nach diesen Meldungen wieder mal bewegt,das schönste wäre ja, dass mal Aufträge rein kommen.
Mal abwarten

[nort_de]

Ein paar News für den Start in die nächste Woche...

+ 18.11.2005 + Vietnam und China kündigen drastische Maßnahmen gegen die Vogelgrippe an: China impft 14 Milliarden Zuchtvögel, das sind 20 Prozent der weltweiten Geflügelpopulation und Vietnam tötet alle Vögel in den zwei größten Städten des Landes, in Saigon und Hanoi.
Das Fleisch wird eingefroren und soll später verkauft werden. Ursache der neuesten Aktivitäten: vietnamesische Forscher stellten Veränderungen an dem gefährlichen H5N1- Virus fest, die zu einer hohen Ansteckungsgefahr von Mensch zu Mensch führen können. Würde diese Gefahr Realität, droht eine weltweite Epidemie mit Millionen Toten. Westliche Forscher wollen die neuen Meldungen erst kommentieren, wenn sie diese überprüft hätten.

In China ist die Vogelgrippe inzwischen in 11 verschiedenen Regionen aufgetreten. Bisher fielen dem Vogelgrippen-Virus H5N1 in Asien 125 Menschen zum Opfer. In Asien leben Menschen und Hühner enger zusammen als sonst wo in der Welt. Die bisherigen Opfer hatten sich nicht von Menschen, sondern von Vögeln angesteckt. Jetzt musste auch China erstmals mehrere Fälle von Vogelgrippe-Infektionen bei Menschen einräumen. Zwei Patienten sind offenbar gestorben.
Quelle:
Franz Alt 2005




US-Präsident fordert Hu zu mehr Religionsfreiheit in China auf
20.11.2005 05:11

PEKING - Chinas Staats- und Parteichef Hu Jintao hat in Peking US-Präsident George W. Bush empfangen. ....

China und die USA vereinbarten auch eine verstärkte Kooperation im Kampf gegen die Vogelgrippe und vorbeugende Massnahmen gegen eine mögliche Pandemie.

Beide Seiten wollen bei der Entwicklung von Impfstoffen, der Beobachtung der Krankheit, der Ausbildung von Personal und der Entwicklung von Strategien für den befürchteten Ausbruch der Vogelgrippe auch unter Menschen kooperieren.


http://www.wams.de/data/2005/11/20/806270.html?s=1

[DagobertDuck57]

Leute, jetzt wird´s Krass!!!
Dass der Vogelgrippen-Virus auch auf die Klapperstörche überging, wurde jetzt in China festgestellt!!
Aufgrund der Tatsache dass der Klapperstorch die Babys liefert, wird jetzt mit einer hohen Geburtensterblichkeit
gerechnet
Gruss

[nort_de]

[posting]18.888.995 von DagobertDuck57 am 20.11.05 14:20:31[/posting]was natürlich bei der 1-Kind Regelung einen imensen volkswirtschaftlichen Schaden anrichtet... Also nichts wie raus aus Chinafonds...

[Stochastic]

Gefällt mir sehr gut wie CBMX konsolidiert!!

Wahrlich bilderbuchmäßig bisher....jetzt annähern an die unteren BBD nach Bruch des Durchschnitts....sehr schön....wenn die so weitermachen sehe ich gute Chancen auf eine neue Welle in den nächsten Wochen!

[nort_de]

[posting]18.924.477 von Stochastic am 21.11.05 16:19:06[/posting]man soll den Tag nicht vor dem Abend loben...

[Stochastic]

[posting]18.934.644 von nort_de am 22.11.05 10:23:19[/posting] bleiben....noch läuft alles, wie im Bilderbuch....heute könnte es dann bis 1,60 runtergehen!

[italy05]

wenn ich pari bin verkauf ich den schrott

[buxte]

[posting]18.937.137 von italy05 am 22.11.05 13:37:13[/posting]wieso Schrott?

[DagobertDuck57]

Sollte sie nochmals bis 1,08€ fallen, dann werde ich
auf jeden Fall N A C H K A U F E N !!!!!!!!
Gruss

[italy05]

seit die Aktie bei 2,20 war gehts nur noch in einer richtung,u zwar alle Tage,sowas ist für mich schrott

[buxte]

[posting]18.939.697 von italy05 am 22.11.05 15:49:21[/posting]dann würde ich aber jetzt gerade drin bleiben. Hast ja fast die ganze Konso mitgemacht. Jetzt auszusteigen wäre m.E. nach die falsche Lösung.

buxte

[italy05]

Wenn ich jetzt verkaufen würde wär ich arg in minus

Verkaufe wenn ich pari bin

Grüße

[nort_de]

Acacia Technologies Acquires Rights to Patents for Archiving and Transmitting Medical Images
Tuesday November 29, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Nov. 29, 2005--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that Acacia Patent Acquisition Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, a leader in technology licensing, has acquired rights to patents relating to Picture Archiving and Communications Systems (PACS) used in archiving and transmitting medical images.

ADVERTISEMENT
"Acacia`s revenue growth in 2005 is primarily being driven by new licensing programs for patented technologies that we acquired this year," commented Paul Ryan, Chairman and CEO of Acacia. "The PACS technology is the 32nd patented technology that we have acquired this year. We plan to continue acquiring new patent portfolios as we move more toward our goal of becoming the leader in technology licensing," concluded Mr. Ryan.

PACS enable multiple, remote users to simultaneously access image data from remote display terminals over common phone and data networks, such as the Internet. PACS are commonly used by hospitals to acquire, store, archive and transmit patient image data for remote access by their physicians, at their homes, offices or within the hospital at the point of care.

[DagobertDuck57]

Noch ein Leichenspezialist

Dr. Jonathan W. Said Joins CombiMatrix Molecular Diagnostics` Scientific Advisory Board


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Nov. 30, 2005--Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that Dr. Jonathan W. Said, M.D. has joined CombiMatrix`s wholly owned subsidiary, CombiMatrix Molecular Diagnostics (CMD), as a member of its Scientific Advisory Board. Dr. Said is a board certified Anatomic Pathologist who is currently Chief, Division of Anatomic Pathology, Department of Pathology and Laboratory Medicine and Chief, Surgical Pathology at UCLA Medical Center for the Health Sciences. He is also Professor of Pathology and Urology at UCLA School of Medicine.

"CombiMatrix Molecular Diagnostics is a true innovator in the development of molecular cancer diagnostics," stated Dr. Said. "I look forward to working with this team and am very excited about the future of CMD."

"We are very pleased that Jonathan is joining CMD`s Scientific Advisory Board to provide critical knowledge in the area of lymphoma molecular pathology," said Matthew Watson, CEO of CombiMatrix Molecular Diagnostics. "We look forward to his insight and leadership as we begin to launch our diagnostic services."

Dr. Said is a prominent expert in the field of molecular diagnostics, with a particular focus on lymphoma. He is active in the United States, Canadian, and International Academy of Pathology, American Society for Hematopathology, American Society of Hematology, and College of American Pathologists. He is a well-known lecturer and has authored and co-authored articles in many peer-review journals including American Journal of Pathology, American Journal of Clinical Pathology, Cancer, Human Pathology, and New England Journal of Medicine.

Dr. Said received his medical degree from the University of Witwatersrand Medical School, Johannesburg, South Africa. He completed his residencies in pathology at the Mallory Institute of Pathology and Peter Bent Brigham Hospital, Boston, Massachusetts. He served a fellowship in Hematopathology at Peter Bent Brigham Hospital and fellowships in clinical and research pathology at Harvard Medical School -- http://www.healthcare.ucla.edu/institution/physician?personn…

[sadawake]

Diese Pressemeldung wurde vor einigen Minuten veröffentlicht, und wird dem Titel weiteren Schwung geben:


CombiMatrix Enters into Distribution Agreement with Singapore-Based Cell Sciences
Thursday December 1, 3:03 pm ET
Cell Sciences to Distribute Arrays Including CombiMatrix`s New Influenza Array

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Dec. 1, 2005--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has entered into a non-exclusive distribution agreement with Cell Sciences Pte Ltd, a wholly owned subsidiary of the CyGenics Group, to distribute CombiMatrix products and services in Singapore, Malaysia, Thailand, Philippines, Hong Kong, and Indonesia. Under the terms of the agreement, Cell Sciences will market and sell CustomArrays(TM) and CatalogArrays(TM), including the recently introduced Influenza Research Microarray.

ADVERTISEMENT
"We are very pleased to have expanded our distribution network into South East Asia," said Michael Tognotti, Vice President of Sales and Marketing for CombiMatrix. "I am confident that by joining forces with Cell Sciences, we can accelerate sales growth and enhance our collective market share."

"Cell Sciences has identified CombiMatrix`s platform technology to rapidly produce customizable arrays for applications in the areas of proteomics, genomics and nanotechnology," said Dr. John Khong, Vice President & General Manager, Cell Sciences. "This has a huge market potential in the Asia Pacific region and we look forward to a long and fruitful relationship. In addition, we are impressed with CombiMatrix`s recently launched influenza array. As we enter the flu season, and focus on H5N1 intensifies, we anticipate increased interest in this array."


Gruss

SAD

[nort_de]

[posting]19.126.275 von sadawake am 01.12.05 21:30:19[/posting]erst cbmx und dann nvax

[CEO2000]

+11% in US zum schluß
da geht morgen die lutzi ab

mfg ceo